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Abstract 
The American Cancer Society estimates that in the year 2017, approximately 40,000 
women will die from breast cancer. The vast majority of these breast cancer cases (80-85%) 
are sporadic in nature, developing spontaneously within the lifetime of a woman. While there 
is a significant amount of knowledge regarding the genetic drivers of hereditary breast 
cancers, there is very little known about the genes responsible for driving sporadic breast 
cancers, largely in part due to the dearth of appropriate mouse models of this disease. The 
C3H-MCM4Chaos3(Chaos3) mouse model bears a single endogenous mutation in a gene 
encoding a component of the MCM2-7 replication helicase, which our lab has previously 
shown results in a state of chronic replication stress and downstream genomic instability, 
leading to a strain-specific phenotype of female mice developing spontaneous mammary 
adenocarcinomas. In my graduate research work, I have utilized this powerful and unique 
mouse model to determine the genetic drivers of these sporadic mammary tumors (MTs), 
based on relevance to human breast cancer data available publicly. My analyses of recurrent 
genomic alterations present in these Chaos3 MTs revealed that the majority of them (>80%) 
contained heterozygous deletions of a gene encoding the chromatin remodeling component 
Arid1a. Importantly, ARID1A is also frequently deleted (monoallelically) in a significant 
  
subset of human breast cancers (between 30-50%, depending on the specific study cited), 
based on data from The Cancer Genome Atlas (TCGA). I have characterized the pathways 
being altered upon overexpression of Arid1a in Chaos3 MT cells, and have identified potential 
direct transcriptional targets of Arid1a regulation using this in vitro system. I have further 
shown that the heterozygous loss of Arid1a is a critical maintenance factor for MT growth in 
this model, and that endogenous induction of Arid1a expression to wild-type levels is 
sufficient to significantly slow down MT cell proliferation in vitro. This is suggestive of a 
haploinsufficient role for Arid1a tumor suppression, in a manner similar to TP53, and offers 
an intriguing therapeutic opportunity of inducing the remaining ARID1A allele to potentially 
reduce MT growth in the subset of human breast cancers that retain an intact copy of this 
powerful tumor suppressor gene. 
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CHAPTER 1 
Introduction 
 
As of 2017, breast cancer accounts for 30% of all new cancer diagnoses in 
women, resulting in the second highest number of cancer-related deaths in women 
annually in the United States alone1. The vast majority of these tumors (~70%) 
develop spontaneously within the lifetime of a woman, and are characterized as 
sporadic breast cancers2. While extensive research over the past few decades has 
revealed the most important genetic drivers of hereditary/familial breast cancers, the 
genetic basis for sporadic breast cancers in women is still unclear. This dissertation 
will focus on characterizing a potential genetic driver of sporadic breast cancer, 
Arid1a, using a unique mouse model for this disease. 
 
1.1. Mouse models for Breast Cancer 
Recent large-scale human cancer genome screens such as The Cancer Genome 
Atlas (TCGA) have catalogued in great magnitude and detail the genetic alterations 
found in several different cancer types. While this information has greatly increased 
our understanding of the comparative landscapes of human tumor genotypes, the 
significant challenge of differentiating between driver events that play a causal role in 
carcinogenesis and passenger events that are not required for tumor 
growth/maintenance still remains. The diversity of human patient populations and the 
heterogeneity of tumor etiology within these patients renders this kind of analyses near 
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impossible, which is why the use of mouse models is necessary to be able to further 
validate/invalidate these candidate cancer genes and elucidate their mechanistic 
functions. 
Genetically engineered mouse models (GEMMs) have contributed extensively 
to our knowledge and understanding of the function of several important breast cancer 
genes, including tumor suppressors such as Brca1/2, Tp53 and Pten, and oncogenes 
such as Erbb2, Hras, Myc, and Ccnd13. GEMMs of breast cancer have improved 
greatly through advances in genetic engineering over the years, which have enabled 
greater spatiotemporal control of mammary tumor onset, most commonly by using 
mammary-specific promoters (Wap or MMTV) to drive Cre-mediated gene 
deletion/activation. While this has facilitated the targeting of tumor initiating events to 
a smaller fraction of cells within the mammary gland, it still does not fully recapitulate 
the natural development of sporadic breast cancers, which are believed to evolve from 
initiating events within a single cell4. Additionally, the vast majority of GEMMs of 
breast cancer are based on the induction of specific molecular changes that are known 
to result in sustained cell proliferation, with very little focus on lesser understood 
hallmarks that are now accepted to be central to cancer development, such as DNA 
replication stress and genomic instability5,6.  
Thus, there is a scarcity of information available for the genetic/epigenetic 
basis of sporadic breast carcinogenesis, mainly due to the lack of appropriate mouse 
models of the disease.  
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1.2. The Chaos3 Mouse Model for Sporadic Breast Cancer 
The Chromosome Aberrations Occurring Spontaneously 3 (Chaos3) mouse 
model for sporadic breast cancer is unique in that these mice develop spontaneous 
mammary tumors at a very high frequency without the specific targeting of known 
breast cancer genes or treatment with external carcinogens.  
The model is derived from a single nonsynonymous point mutation in the 
minichromosome maintenance 4 (Mcm4) gene. Mcm4 is a highly conserved subunit of 
the MCM2-7 replication helicase complex, which is essential for initiating DNA 
replication in all eukaryotic cells7. The nature of the viable hypomorphic Chaos3 allele 
results in destabilization of the MCM2-7 helicase in a manner that compromises 
normal DNA replication licensing by reducing the number of dormant replication 
origins8. This in turn causes downstream replication stress via the accumulation of 
stalled replication forks, and ultimately leads to an increase in genomic instability and 
cancer incidence in mouse strains bearing this allele8-10.  
When congenic in the C3HeB/FeJ (C3H) strain, nearly all female mice with 
Chaos3 homozygosity succumb to mammary adenocarcinomas with an average 
latency of 12 months11. The mammary tumor phenotype is strain-specific, with 
progeny from hybrid crosses of C57BL/6J (B6) mice bearing the Chaos3 allele 
resulting in a different spectrum of tumor phenotypes11. This observation led to the 
identification of a nonsynonomous point mutation in the Talin1 (Tln1) gene present in 
our Chaos3 model that predisposes to mammary tumor formation, following QTL 
mapping of susceptibility and resistance loci in C3H x B6 offspring (MD Wallace et 
al., unpublished; see Appendix). Other studies using this model have shown that 
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mouse viability is also affected by the genetic background in which the Chaos3 allele 
exists, with increased lethality observed in B6 mice, due to strain-specific dynamics 
between the number and density of licensed and dormant replication origins10. Taken 
together, these genetic and biochemical data in large part help explain the unique 
mammary tumor phenotype of the Chaos3 mouse model. 
 
1.3. Relevance of the Chaos3 Model to Human Breast Cancer 
Previous work in the lab has compared gene expression profiles of the Chaos3 
mouse mammary tumors (MTs) with that of other well established GEMMs of breast 
cancer, and found that the expression signature of Chaos3 MTs most closely 
resembles that of mature human mammary luminal cells, and when compared to all 
the major subtypes of human breast cancer based on clinical diagnoses, the Chaos3 
MT signature was most highly expressed in the luminal A subtype12. Luminal A 
tumors are the most prevalent subtype of human breast cancers, accounting for 64% 
and 48% of breast cancers diagnosed in populations of white and African American 
women, respectively13.  
The controlled genetic background and consistent etiology of the Chaos3 MTs 
enables the characterization of recurrent genetic events that may play driving roles in 
mammary carcinogenesis. Array-based Comparative Genomic Hybridization (aCGH) 
experiments were conducted by previous lab members and myself, with the goal of 
identifying DNA copy number variations (CNVs) specific to Chaos3 MTs. These 
experiments have led to the discovery of CNVs spanning large regions of the genome 
that are recurrently amplified or deleted within the Chaos3 MTs. Several of these 
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regions also correspond to CNVs frequently present in human breast cancers, as 
characterized by TCGA studies12,14.  
In summary, these data demonstrate the usefulness and relevance of the 
Chaos3 mouse model as a means to identify potential drivers of sporadic breast 
cancer. 
 
1.4 Genomic Instability as a Hallmark of Cancer 
Genomic instability (GIN) is predominantly characterized by an increased rate 
of both structural and numerical chromosomal aberrations, which is found to occur at 
a much higher frequency in cancer cells relative to normal cells over time15. In 
hereditary cancers, GIN is driven by germline mutations in DNA repair genes such as 
BRCA1, BRCA2, PALB2 and BRIP1 (breast and ovarian cancers)16, NBS1 and RAD50 
(non-Hodgkin lymphoma and brain cancers)17, WRN, BLM and REQL4 (broad 
spectrum of cancers)18, and Fanconi Anaemia genes (acute myeloid leukemia)19. 
These genetic observations in individuals predisposed to cancer strongly supports the 
mutator hypothesis, which states that GIN may be present in precancerous lesions and 
can drive tumor progression by increasing the rate of spontaneous muations20. 
In sporadic cancers, the molecular basis and significance of GIN is less clear. 
Recent advances in the molecular and genetic analysis of the genomes of cancer cells 
have provided the most compelling evidence for enduring GIN in tumor progression. 
aCGH experiments in particular have revealed prevalent genomic aberrations 
(amplifications and deletions) across different tumor types, and importantly have 
identified recurrent CNVs at specific genomic locations, suggestive of the presence of 
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genes whose alteration favors neoplastic formation/progression21. Specifically, with 
respect to recurrent genomic deletions in cancer, proteins encoded by genes present 
within these regions have been found to play important roles in maintaining genomic 
integrity through the DNA damage response (DDR)22,23. Additionally, recent next-
generation sequencing of cancer genomes has identified widespread 
alterations/mutations in known DNA repair genes, such as BRCA1/BRCA2 
(homologous repair genes), KU70/80 (non-homologous repair genes), and 
MLH1/MLH2 (mismatch repair genes) in leukemias, prostate and breast cancers24-26. 
The organ-specific cancer risk associated with these types of genetic aberrations is 
suggestive of cell-type specific vulnerabilities to extrinsic/intrinsic factors, and more 
work needs to be done to elucidate these mechanisms. 
Thus, there is growing evidence for a model of carcinogenesis in which loss of 
function of genes involved with the DDR can act as an instigator of GIN, which then 
leads to the acquisition of additional mutational events that may be selected for during 
tumor progression. One important set back in proving this model is the limited 
knowledge we have of all potential “caretaker genes” that play a critical role in 
maintaining genomic integrity. As technology advances and we garner more 
information from large-scale cancer genome screens, it will be essential to further 
characterize the function of the genes identified as being altered/mutated at high 
frequencies, as this could add to our incomplete understanding of 
pathways/mechanisms that are involved with protecting the genome against malignant 
transformation.  
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For example, only recently have we begun to understand the critical roles that 
ATPase-dependent mammalian SWItch/ Sucrose Non-Fermentable (mSWI/SNF) 
chromatin remodeling complexes and their individual components play as “caretakers” 
of the genome. Multiple studies published in the last five years or so have shown 
differential involvement of mSWI/SNF subunits in DNA double-strand break repair, 
non-homologous end joining, replication-associated decatenation, sister chromatid 
cohesion and DNA damage-induced transcriptional repression27-30. Since we know 
that reduced or loss of function of these important pathways can lead to chromosome 
mis-segregation/aneupoliody, structural chromosomal instability, and abnormal 
growth signaling, all of which contribute to carcinogenesis, the loss of mSWI/SNF 
function may in fact lead to compromised genome integrity as a result of the 
simultaneous aberration of these crucial pathways27. 
 
1.5 Epigenetic Mechanisms of Tumor Suppression 
In recent years, our knowledge of the processes by which genes are regulated 
has greatly broadened to include the epigenetic effects of chromatin structure and its 
impact on gene function. Currently, epigenetics is defined as ‘the study of heritable 
changes in gene expression that occur independent of changes in the primary DNA 
sequence’31. Most of these changes are heritable and stable within cells, and are 
required during normal mammalian development for establishing and maintaining 
tissue-specific gene expression. Failure to maintain these inherited epigenetic marks 
has been found to result in the dysregulation of important signaling pathways, 
resulting in diseases such as cancer32. 
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Epigenetic aberrations in cancer may occur in the form of disordered DNA 
methylation patterns, histone modifications and/or nucleosome positioning, all of 
which ultimately result in dysregulated gene expression33. TCGA data has revealed 
that in addition to numerous genetic alterations, tumors of various types also harbor 
widespread epigenetic alterations at a very high frequency34,35. Like genetic changes, 
epigenetic changes affect cancer development at all stages, and in most cases, they 
appear to work together to promote cancer progression33,36,37. Thus, taken together, the 
evidence suggests an intertwining of genetic and epigenetic events as the most 
prevalent model of carcinogenesis. 
Relevant to my research is the idea that genetic alterations in epigenetic 
regulators may lead to an altered epigenome and ultimately cellular transformation. 
The most compelling evidence for this is the recent discovery that nucleosome 
modelers are mutated/altered at very high frequencies in human cancers of various 
types39-42. These types of mutations/alterations may have catastrophic effects on gene 
expression, based on the role of nucleosome modifiers in genome-wide transcriptional 
regulation39,40,42. One of the most recurrently deleted chromosomal regions identified 
by aCGH analysis of Chaos3 MTs bears the gene Arid1a, which encodes a member of 
the mSWI/SNF chromatin remodeling complex, the most highly altered/mutated 
nucleosome modeler in cancer43-46. Experimentally, our results have shown that 
genetic loss of Arid1a is a maintenance factor in MT cells derived from this model, 
and that Arid1a may behave as a haploinsufficient tumor suppressor, with dosage 
effects playing a key role in cell proliferation and growth. Although mounting 
functional evidence has led to the acceptance of ARID1A as a bona fide tumor 
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suppressor gene47,48, the epigenetic extent of its role in altering chromatin structure by 
contributing to mSWI/SNF activity, modulating gene transcription and ultimately 
suppressing cancer formation is yet to be fully elucidated. My research work described 
in the following chapters attempts to shed more light on the tumor suppressive 
mechanisms of Arid1a activity. 
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2.1 Abstract 
Human cancer genome studies have identified the SWI/SNF chromatin 
remodeling complex member ARID1A as one of the most frequently altered genes in 
several tumor types. Its role as an ovarian tumor suppressor has been supported in 
compound knockout mice. Here, we provide genetic and functional evidence that 
Arid1a is a bona fide mammary tumor suppressor, using the Chaos3 (Chromosome 
aberrations occurring spontaneously 3) mouse model of sporadic breast cancer. About 
70% of mammary tumors that formed in these mice contained a spontaneous deletion 
removing all or part of one Arid1a allele. Restoration of Arid1a expression in a 
Chaos3 mammary tumor line with low Arid1a levels greatly impaired its ability to 
form tumors following injection into cleared mammary glands, indicating that 
ARID1A insufficiency is crucial for maintenance of these Trp53-proficient tumors. 
Transcriptome analysis of tumor cells before and after re-introduction of Arid1a 
expression revealed alterations in growth signaling and cell-cycle checkpoint 
pathways, in particular the activation of the TRP53 pathway. Consistent with the 
latter, Arid1a re-expression in tumor cells led to increased p21 (Cdkn1a) expression 
and dramatic accumulation of cells in G2 phase of the cell cycle. These results not 
only provide in vivo evidence for a tumor suppressive and/or maintenance role in 
breast cancer, but also indicate a potential opportunity for therapeutic intervention in 
ARID1A-deficient human breast cancer subtypes that retain one intact copy of the 
gene and also maintain wild-type TRP53 activity. 
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2.2 Introduction  
The identification of genetic drivers of specific types and subtypes of cancer 
continues to be an important goal of cancer biology research. Major efforts including 
The Cancer Genome Atlas (TCGA) project have catalogued mutations in diverse 
human tumors. This wealth of data has been instrumental in identifying genes that 
may be playing a direct or indirect role in carcinogenesis by virtue of them being 
commonly altered in a particular cancer type. However, proving causality of these 
candidate “driver” genes, and elucidating their roles in tumorigenesis, requires 
relevant experimental validation.  
 ARID1A (also called BAF250a), encoding an important component of 
the mammalian SWI/SNF complex, has emerged as one of the most commonly 
mutated or downregulated genes in diverse tumors, including gastrointestinal1,2, 
endometrial3,4, ovarian clear cell5,6, pancreatic7, lung8 and breast9,10. ARID1A impacts 
epigenetic gene regulation by altering chromatin structure around promoters of 
specific loci in conjunction with its associated SWI/SNF complex components11,12. 
Therefore, its downregulation or mutation in somatic cells can have profound 
consequences including inappropriate proliferation13. Despite the accumulating 
correlative data implicating ARID1A as a tumor suppressor, functional proof has been 
lacking in part due to the fact that knockout of Arid1a in mice causes embryonic 
lethality even in the heterozygous state14. However, two recent reports have shown 
that conditional biallelic knockout of Arid1a in ovarian surface epithelial cells, in 
conjunction with either conditional expression of a mutant phosphoinositide 3-kinase 
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catalytic subunit PIK3CA15, or conditional disruption of Pten16, caused carcinomas 
resembling clear cell in the former, and endometriod/undifferentiated in the latter. In 
both studies, deletion of Arid1a alone, or deletion of only one Arid1a allele in the 
compound mutant situations, was insufficient to cause cancer. While these studies 
provided compelling evidence for the tumor suppressive role of Arid1a in ovarian 
cancer, they (and most other genetically-engineered cancer models) do not model the 
process of sporadic cancer development. Furthermore, the dependency of bi-allelic 
Arid1a inactivation upon mutation of Pten or Pik3ca in driving tumor formation in 
these models seems to be specific to the pathogenesis of endometrium-related ovarian 
neoplasms17 and does not appear to apply to several of the other human cancers in 
which ARID1A is commonly mutated18. Thus, it is important to validate cancer genes/ 
pathways in the context of their tumor-type-specific environments, as the behavior of 
these genes and pathways may vary by tissue type. Sporadic breast cancer (i.e., not 
associated with inherited neoplasia-driving mutations) accounts for the vast majority 
of breast cancer cases worldwide (90-95%)19. Although ARID1A has not yet been 
widely recognized as key suppressor of breast carcinogenesis, it is heterozygously 
deleted in a substantial fraction of tumors9,10, and low ARID1A expression in tumors of 
breast cancer patients correlates significantly with poorer prognosis and overall 
survival20. Here, we report functional evidence that Arid1a loss is critical for 
mammary tumorigenesis in a mouse model of spontaneous breast cancer, and present 
data on how this leads to deregulated cancer cell growth. 
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2.3 Results and Discussion 
The Chaos3 mouse, bearing a missense allele (Mcm4Chaos3) of the DNA 
replication gene Mcm4, exhibits high levels of genomic instability caused by the 
mutation’s destabilization of the MCM2-7 replicative helicase complex 21-23. Most 
females homozygous for the Chaos3 mutation congenic in the C3HeB/FeJ strain 
background (“Chaos3”) develop spontaneous mammary tumors (MTs) with an 
average latency of twelve months21. Array Comparative Genomic Hybridization 
(aCGH) analyses of 9 Chaos3 MTs revealed interstitial deletions common to a small 
number of chromosomal regions24. Almost all tumors were missing both copies of 
Nf1, a tumor suppressor that functions as negative regulator of Ras, but positive for 
Trp5325.  
Those aCGH data, plus an additional 12 reported here, indicated that most 
(18/21) MTs also contained deletions involving part or all of an ~100kb region on 
Chr4 containing Arid1a (Figure 2-1). To further validate the aCGH results, we 
performed digital droplet PCR (ddPCR) on DNA from the same 12 MTs + 3 non-MTs 
using probes situated at both ends of Arid1a. All 15 calls for Probe 2, and 13/15 for 
Probe 1 (Figure 2-1A) were consonant. The two discrepancies were in MTs 7 and 12, 
which according to aCGH results, have an identical deletion breakpoint within Arid1a. 
It is possible that in these cases, the breakpoint is actually proximal to that called by 
the software. As an alternative confirmation of Arid1a hemizygosity in these tumors, 
we took advantage of genetic polymorphisms in two F1 (C3HeB/FeJ x C57BL/6J) 
MTs deleted for Arid1a (#1 and #8, Figure 2-1) and an F2 MT having no deletion (#2 
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in Figure 2-1), based on aCGH calls. Genotyping of SNPs at the 3’ end of Arid1a 
revealed agreement with the aCGH and ddPCR data (Figure 2-1A; S2-1).  
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Figure 2-1: Arid1a is recurrently deleted in Chaos3 mammary tumors. (A) 
Overview of aCGH data near the Arid1a locus from 15 tumor samples, adapted from an 
IGV depiction. Solid lines denote stretches of contiguous probes with reduced 
hybridization signal, thus representing deleted regions. Nucleotide coordinates of 
deletion endpoints are indicated, and correspond to the last probe with reduced 
hybridization signal on the array. MT = mammary tumor. The control non-MTs consist 
of 2 uterine tumors and 1 bone tumor. (B) Plot of probe intensities near the Arid1a from 
aCGH hybridization. Each dot is a probe on the array, with the green and red 
representing control vs tumors, respectively. Locations of primer pairs used for Arid1a 
CNV analyses by ddPCR are depicted in the figure as P1 and P2 (see Methods). 
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We next scored 33 additional Chaos3 MTs and 5 cell lines derived from 
Chaos3 MTs for deletions in the Arid1a coding region by ddPCR. In total, ~70% of 
the Chaos3 MTs analyzed had monoallelic deletions for all or part of Arid1a (Table 
S2-1). Hemizygosity for ARID1A also appears to be common in human breast 
carcinomas at frequencies as high as ~40% depending on the dataset26-28 (Fig. S2-2).  
If hemizygosity of Arid1a contributes to tumorigenesis, then either it is 
haploinsufficient (i.e., 50% expression contributes to the transformed state), or the 
non-deleted allele is also altered in a genetic or epigenetic manner that reduces Arid1a 
expression to a level below that which is necessary to prevent transformation and/or 
tumor growth. To test this, we quantified Arid1a mRNA in hemizygous and non-
deleted Chaos3 MTs. On average, transcript levels in 24 Arid1a-deleted tumors, but 
not non-deleted tumors, averaged about half that present in WT mammary tissue (Fig. 
2-2; Table S2-2). The results suggest that ARID1A reduction, but not elimination, may 
contribute to tumorigenesis or tumor maintenance. Interestingly, the two Chaos3 non-
mammary tumors tested had ~5 fold more Arid1a than the deleted MTs (Fig. 2-2). 
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Figure 2-2. Tumors hemizygous for Arid1a have less Arid1a mRNA.  
Plotted are qRT-PCR expression data from the Chaos3 non-MTs (two uterine tumors) 
and Chaos3 MTs that were either heterozygously deleted (n = 21) or not deleted (n = 
5) for ARID1A, based on ddPCR data. Expression levels for each sample were 
calculated relative to an average of two WT RNA tissue samples. Significant 
differences were calculated using a two-tailed Student’s t-test (** P < 0.001). 
 
 
 
 
 
 
 
 21 
 
The genetic and molecular data described above implicate, but do not prove, 
that decreased ARID1A expression is involved in either neoplastic transformation or 
maintenance of the transformed state. To address this question functionally, we 
conducted experiments to restore Arid1a expression in ARID1A-deficient Chaos3 MT 
cells, followed by analyses of the in vitro and in vivo consequences. First, we 
generated a Chaos3 mammary tumor cell line (23116 MT) that has one copy of Arid1a 
deleted (Table S2-1) and very low levels of Arid1a expression (Fig. 2-3A, B), then 
stably introduced an Arid1a cDNA expression construct into these cells using 
lentivirus-mediated transduction. These transformed lines were termed “Addback” 
(AB) cells. We then assessed cell proliferation activity via EdU incorporation in the 
parental vs. three transduced cell lines, and found that ectopic Arid1a expression 
caused a dramatic decrease (~3 fold) in EdU incorporation in each of the lines tested 
(Fig. 2-3C). 
To determine if ARID1A is required for tumorigenicity, we tested whether one 
of the transduced clones (AB-C1) exhibiting elevated levels of mRNA (Fig. 2-3A) and 
protein (Fig. 2-3B) would reduce/abolish the ability of 23116 MT cells to form tumors 
when transplanted into host animals. The parental and AB-C1 cancer cells were 
injected into cleared mammary fat pads of WT C3H female mice (23116 MT on one 
side, and AB-C1 on the other of each mouse, see Materials and Methods), and 
monitored for tumor formation. Overexpression of Arid1a significantly decreased 
mammary tumor formation frequency and size (Fig. 2-3D). These results indicate that 
loss/reduction of Arid1a expression is crucial for the growth and/or formation of 
Chaos3 mammary tumors. As shown below, ectopic Arid1a overexpression did not 
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inhibit tumor formation in an unrelated non-Chaos3 MT cell line MCN1, indicating 
that excessive ARID1A itself is not cell toxic. 
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Figure 2-3. Overexpression of Arid1a in Chaos3 MT cell line reduces proliferation 
rate and prevents tumor growth. (A) Arid1a expression levels quantified by qRT-
PCR in untransduced Chaos3 MT cell line (23116 MT) and three individual clonal 
lines (AB-C1, AB-C2, and AB-C3) transduced with the Arid1a expression vector. 
Results are shown as the mean 6 SEM of three technical replicates. Significant 
differences were calculated using a two-tailed Student’s t-test (* P < 0.05; ** P< 
0.001). Values are relative to untransduced parental cell line 23116 MT. (B) Arid1a 
expression levels quantified by immunoblotting in indicated cell lines. (C) EdU 
incorporation assays of 23116 MT vs. AB clones (C1–C3). Error bars signify the SEM 
of three experimental replicates, with >1000 cells counted per sample for each 
replicate. Significant differences were calculated using a two-tailed Student’s t-test. 
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To gain insight into the mechanisms by which Arid1a loss promotes 
tumorigenesis in the Chaos3 model, we considered data showing that Arid1a is 
required for efficient functioning of the DNA damage response (DDR), specifically 
the G2/M cell-cycle checkpoint that helps suppress genomic instability (GIN) and 
tumorigenesis29,30. Since Chaos3 cells have chronic replication stress and GIN
21,23,31, it 
is possible that a loss or reduction of ARID1A in a cell allows escape from DDR-
mediated growth arrest or apoptosis, thus promoting carcinogenesis. Therefore, we 
examined the cell cycle of AB-C1 cultures. This revealed an accumulation of cells in 
the G2 phase (Fig. 2-4A & B), suggesting that Arid1a overexpression might be 
inducing a checkpoint response and consequent growth arrest. 
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Figure 2-4. Cell-cycle analysis of Chaos3 mammary tumor cell lines. (A) Cell-
cycle profiles of 23116 and AB-C1 mammary tumor lines. (B) Percentage of cells in 
different phases of the cell cycle (G1, S, and G2) based on FloJo statistical analyses. 
Significant differences were calculated using a two-tailed Student’s t-test (* P < 0.05; 
** P < 0.001). Values are relative to untransduced parental cell line 23116 MT. 
 
 
 
 
 
 26 
 
Since ectopic Arid1a expression in ARID1A-deficient MT cells caused cell 
cycle arrest, we assessed whether either senescence or apoptosis was triggered as a 
consequence. TUNEL assays did not reveal a significant increase in apoptosis, based 
on relative percentages of positively stained cells (23116 MT = 0.6%, ± 0.2% S.E.M.; 
AB-C1 = 1.5%, ± 0.4%), raising the possibility that these cells were instead 
senescing. Another indication was the dramatic change in morphological features of 
the cells in which Arid1a was overexpressed. They appeared larger and flatter (Fig. 
5A), characteristic of cells undergoing senescence 32. Finally, we conducted 
senescence-associated beta-galactosidase (SABG) assays, showing that the AB-C1 cell 
population had nearly 10 fold more SABG-positive cells than the parental cultures 
(Fig. 2-5B & C).  
Multiple studies have demonstrated that DNA damage-induced G2 arrest 
activates cellular senescence in a TRP53- and p21-dependent manner33-35. mRNA 
levels of p21, which is transcriptionally regulated by TRP53, was ~5-fold higher in 
AB-C1 MT cells compared to the 23116 parental line (Fig. 2-5D). Taken together, 
these data indicate that restoring or overexpressing Arid1a in Chaos3 MT cells enables 
G2/M arrest and subsequent cellular senescence. This is consistent with data 
indicating that ARID1A functions as both a “gatekeeper” in its control of cell 
proliferation, and a “caretaker” in its maintenance of genomic integrity 36. 
To better understand the mechanism by which restoration/overexpression of 
Arid1a impairs growth and tumorigenesis, we conducted RNA-seq comparing the 
transcriptomes of 23116 MT vs AB-C1 and AB-C2 cells. A total of 554 genes were 
significantly differentially expressed (DE) between the parental stock and the Arid1a-
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transduced lines (FPKM > 5; Log2 Fold > 1; Table S3). Ingenuity Pathway Analysis 
(IPA) of these DE genes revealed that the TRP53 pathway was activated in AB-C1/C2 
cells, while the TGF Beta pathway was repressed (Fig. 2-S3).  
RNA-seq data also showed that the most highly upregulated genes within the 
TRP53 pathway in AB-C1 cells were Igfbp5, Igfbp2 and Serpinb2 (Pai-2). We 
validated these data by qRT-PCR (Fig. 2-5E). All three genes have been implicated in 
tumor growth suppression37-39. IGFBP5 was found to activate cellular senescence 
through a TRP53-dependent mechanism in human endothelial cells40. These data 
further support the idea of a TRP53-dependent senescence checkpoint response being 
activated when Arid1a is overexpressed in these cancer cells. 
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Figure 2-5. Senescence characteristics of AB-C1 cancer cells. (A) Morphological 
comparison of 23116 MT vs. AB-C1 cells. (B) Representative images of indicated 
cells stained for senescence-associated ß-galactosidase activity. (C) Average 
percentages of positively stained cells (blue color) calculated from four technical 
replicates. (D) qRT-PCR validation of senescence-associated genes. (E) qRT-PCR 
assay comparing relative transcript levels of p21 in AB-C1 vs. 23116 MT cells. 
Significant differences were calculated using a two-tailed Student’s t-test (* P < 0.05; 
** P < 0.001). Values are relative to untransduced parental cell line 23116 MT. 
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TRP53 was reported to interact physically with ARID1A and the rest of the 
SWI/SNF complex, enabling transcriptional regulation of downstream gene targets 41. 
Several human cancer studies have found that loss of ARID1A expression correlates 
with high amounts of potentially functionally inactive TRP532,42-44, suggesting they 
have co-dependent tumor suppressive functions, and that ARID1A deficiency would 
have a similar effect as losing TRP53 activity. A similar mutually exclusive pattern of 
Trp53 and Arid1a expression seems to exist in Chaos3 MTs. They exhibit high levels 
of TRP5325, but it does not seem to be effective or functional in the sense of its 
established role in suppressing uncontrolled cell growth or malignant transformation. 
Based on this hypothesis as well as the RNA-seq data, it is possible that re-expressing 
Arid1a in the Chaos3 tumor cells restores the ability of TRP53 to regulate downstream 
target genes. 
To test this hypothesis, we overexpressed Arid1a in a Trp53 null mouse 
mammary tumor cell line MCN145, which we found to not only have low Arid1a 
expression (Figure 2-6A, B), but also apparent hemizygosity of Arid1a (Table S2-1). 
EdU incorporation assays comparing the untransduced and AB cells showed that 
unlike the TRP53-proficient Chaos3 cell line 23116, proliferation was unaltered upon 
overexpressing Arid1a in MCN1 (Figure 2-6C), and subsequent mammary fat pad 
growth assays revealed that tumorigenecity in vivo was also unaffected (Figure 2-6D). 
This is consistent with the hypothesis that active TRP53 is necessary for ARID1A to 
function in its tumor suppressive role. 
Chaos3 tumors have a manageable number of recurring spontaneous 
alterations, making it feasible to unravel the molecular events leading to tumor 
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formation – a crucial question in cancer genetics. The experiments here provide 
genetic and functional evidence that ARID1A is a suppressor of mammary 
tumorigenesis, and particularly, that it is required for maintenance of tumorigenic 
potential as revealed by transplantation assays. This role in tumor maintenance also 
appears to be the case in human ovarian cancer, where it was shown that re-
introduction of the gene into tumor cells bearing ARID1A mutations inhibited 
xenograft growth41. Our finding that Arid1a is almost exclusively mono-allelically 
(not bi-allelically) deleted in the Chaos3 model of spontaneous breast cancer, 
apparently similar to the situation in human breast cancers, is important in terms of 
potential therapeutic intervention. We showed that over-expressing Arid1a ectopically 
in MT cells greatly suppresses tumor growth in a TRP53-dependent manner. 
Therefore, in breast cancer cases that retain an intact ARID1A allele in trans to a 
mutant/deleted allele, and also contain wild-type TRP53, it may be possible to employ 
methods for specific reactivation of the remaining allele, thus suppressing tumor 
growth and triggering cell-cycle arrest. Recent development of sequence-specific, 
chimeric transcriptional regulators offers one such potential avenue to accomplish 
this46-50.  
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Figure 2-6. Overexpression of Arid1a in the TRP53-deficient MCN1 has no effect 
on proliferation rate or tumor growth. Arid1a expression levels were quantified by 
(A) qRT-PCR and (B) immunoblotting in MCN1 MT cell line and its transduced 
counterpart cell line (MCN1-C6). Significant differences were calculated using a two- 
tailed Student’s t-test (** P < 0.001). Values are relative to untransduced parental cell 
line MCN1. (C) EdU incorporation assays of MCN1 vs. MCN1-C6. Error bars signify 
SEM of three experimental replicates, with >1000 cells counted per sample for each 
replicate. (D) Representative images of tumors arising from transplantation of MCN1 
(MT-R) and MCN1-C6 (MT-L) cells into cleared fad pads of recipient syngeneic 
FVB/N recipient females. MT-R and MT-L refer to right and left sides of mouse, 
respectively (see Materials and Methods). The right panel plots individual weights of 
tumors (n = 10 mice, 20 tumors). 
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2.4 Materials and Methods  
Cancer cell lines 
 The 23116 MT cell line was generated from a primary mammary tumor that arose 
in a C3H-Chaos3 mouse. The tumor was dissected and mechanical pulverized, then 
seeded on gelatin-coated culture dishes in Dulbecco's Modified Eagle Medium 
(DMEM) supplemented with 10% Fetal Bovine Serum (FBS). “Add-back” (AB) cell 
lines were generated by lentiviral transduction of Arid1a expression vector pLenti-
puro-ARID1A (Addgene plasmid # 39478), followed by puromycin selection (2µg/ml) 
and growth of clonal lines (AB-C1/C2/C3) expressing ectopic Arid1a. All qRT-PCR 
primers are shown in Table S4. 
Array comparative genomic hybridization (aCGH) 
 Genomic DNA was isolated from primary tumors by solubilizing in lysis buffer 
(50 mM Tris-HCl pH 8.0; 100 mM EDTA pH 8.0; 100 mM NaCl; 1% SDS; 0.5 
mg/ml Proteinase K) for 3 hours at 55°, phenol/chloroform extraction, precipitation of 
the DNA in 0.8 volumes isopropanol, followed by spooling and washes in 70% then 
100% ethanol. One µg of genomic DNA was used for labeling and hybridization to the 
SurePrint G3 Mouse Genome CGH Microarray, 1 x 1M (Agilent Product # G4838A). 
Two independent reference WT DNAs (from strain C3HeB/FeJ mammary tissue) 
were used as hybridization controls. This array consists of 60-mer probes with an 
overall median spacing of 1.8kb (1.5kb in Refseq genes). Content for probe design 
was sourced from UCSC mm9 (NCBI Build 37). DNA labeling, hybridization, and 
post-hybridization processing were performed according to the manufacturer’s 
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protocol. Images were scanned using Agilent’s SureScan Microarray Scanner. 
Agilent’s Cytogenomics software was used for spot identification and signal 
quantification, following normalization of test/reference ratios and background 
correction. Criteria for calling amplifications/deletions were as follows: minimum 
number of contiguous probes >= 3, minimum avg. absolute log2 ratio >= 0.25. CNAs 
were visualized using the Integrative Genomics Viewer software package51. 
Droplet Digital PCR 
 Droplet digital PCR (ddPCR) was carried out using the QX200 droplet digital PCR 
system (Bio-Rad Laboratories, Inc., Hercules, CA, USA). ~60ng genomic DNA 
extracted from 51 different tumor samples (Chaos3 MTs and Chaos3 non-MT 
controls) was used per reaction. Individual tumor samples were analyzed for CNVs 
occurring in the target gene Arid1a, by probing two different genomic locations 
spanning the length of the entire gene. Primer and probe combinations used for the 
assay are shown in Table S4. Gapdh was used as a reference gene in CNV analyses. 
Droplet generation and droplet reading for ddPCR were carried out using Bio-Rad 
equipment and reagents, according to the manufacturer’s instructions. Results were 
analyzed using QuantaSoft Software (Bio-Rad) and represented as concentration of 
DNA (copies/μl). Each DNA sample was run in duplicate. Results for all samples 
analyzed are shown Table S2-1. 
qRT-PCR  
Total RNA was isolated from cells and tissues using the E.Z.N.A Total RNA Kit I 
(Omega Biotek). 500ng of RNA was used for cDNA synthesis using the qScript 
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cDNA Supermix kit (Quantabio). qRT-PCR analyses was done using Fast SYBR 
Green Master Mix (Life Technologies) and custom designed primers (Table S4), using 
GAPDH as an endogenous reference. Assays were run on the CFX96 Touch™ Real-
Time PCR Detection System (BIO-RAD). Each sample was run in triplicate wells, 
from which mean Ct values were obtained. Relative quantification of gene expression 
was calculated using the ΔΔCt method. At least two technical replicates were run for 
each experiment to obtain standard error values. 
EdU proliferation assay 
 Cells were grown O/N on coverslips and pulse labeled with 10μM EdU for 30 
minutes. Cells were then fixed with formaldehyde (final concentration of 1%) for 10 
minutes, followed by permeabilization (0.3% Triton X-100 in PBS) for 15 minutes. 
The ‘Click’ reaction cocktail [10mM (+)-sodium-L-ascorbate; 0.1mM 6-
Caboxyfluorescein-TEG azide; 2mM CuSO4] was added to cells and incubated for 30 
minutes at room temperature. Nuclei were counterstained with DAPI and coverslips 
were mounted on slides for EdU-positive cell counting by fluorescence microscopy. 
Experiments were conducted in triplicate, with >1000 cells counted / replicate. 
Mammary fat pad injection surgeries 
 MT cell lines were injected into the #4 and #9 inguinal fat pads of 3-week old 
nulliparous WT C3HeB/FeJ female mice, following clearance of the endogenous 
epithelium. Volume of cells injected / fat pad was 10µl, at a concentration of 1x106 
cells/ml. Tumors were allowed to develop until one grew to ~2cm in diameter, at 
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which point the animals were sacrificed and tissues were collected for analyses. The 
time to tumor formation following surgery varied from 3-12 weeks. 
Cell cycle analyses 
 One million cells were centrifuged and resuspended in 200µl of a cold hypotonic 
solution of propidium iodide (50µg/ml PI, 1mg/ml sodium citrate, and 1µl/ml Triton 
X-100). Cells were incubated at 4°C overnight for complete lysis and staining of 
nuclei. Cell cycle profiles were analyzed using a flow cytometer (BD LSR II), with 
488-nm excitation and emission collected with a 576/26 band-pass filter. Using a PI 
signal-specific width vs. area plot, only single nuclei were included in the analyses of 
all profiles. 
Senescence-associated beta-galactosidase assay 
AB-C1 and 23116 MT cells were seeded onto a 6-well dish at a concentration 
of 0.2 x 106 cells/ml. The next day, cells were stained using a senescence detection kit 
(Abcam, ab65351) as per the manufacturer’s instructions. In brief, cells were fixed for 
10 min at RT with the provided Fixation Solution, and then stained for 16 hrs at 37C. 
The next day, they were visualized using light microscopy for development of blue 
color. Images were taken at 10X magnification and the number of positive cells were 
counted using ImageJ software. Experiments were carried out in triplicate to calculate 
the average percentage values. 
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RNA sequencing 
Total RNA was isolated from replicate samples of 23116 MT and AB clones 
(C1 and C2) cells using the E.Z.N.A. Total RNA Kit I (Omega Biotek). 500 ng/sample 
was used to prepare cDNA libraries, with the NEBNext Poly(A) mRNA Magnetic 
Isolation Module and the NEBNext Ultra Directional RNA Library Prep Kit for 
Illumina (both from NEB). The libraries were then sequenced on Illumina’s Hi-Seq 
platform, generating single-end 100 bp reads. Reads were aligned to the mouse 
genome (UCSC mm10) using Tophat v2.0.1352. Significant differentially-expressed 
(DE) genes between 23116 MT and AB clones were determined with the help of the 
TopHat tool CuffDiff (v2.2.1), which uses a q-value cutoff of 0.05 (q-value = p-value 
corrected for multiple hypothesis testing)52. DE genes were additionally sorted based 
on more stringent criteria where at least one condition (avg. of replicates) must have 
FPKM>=5 and the minimum log2 (fold-change) between conditions is 2-fold (up or 
down). 
Statement on data and reagent availability: Cell lines and constructs are available 
upon request. RNA-seq data and aCGH data are available at the Gene Expression 
Omnibus (accession numbers GSE81575 and GSE81967, respectively). 
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2.6 Supporting Information 
 
 
Figure S2-1. SNP genotyping of Chaos3-MTs. Three individual Arid1a SNPs 
specific to C3HeB/FeJ and C57BL/6J strains were genotyped in F1 and F2 MTs 
derived from mice generated by crossing these two strains, for which aCGH analyses 
was also conducted.  
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Figure S2-2. ARID1A copy number in human breast cancers. Data and analytical 
tools from the cBio portal (http://www.cbioportal.org) were used for generating the 
graph. “Mutation” refers to intragenic mutations such as point changes; “Het. Loss” = 
1 ARID1A copy scored as missing; “Hom. Loss” = no ARID1A copies remaining.   
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Figure S2-3: IPA analyses of RNA-Seq DE genes. Ingenuity Pathway Analyses of 
gene networks altered within the TGFB1 and TP53 pathways in AB-C1and AB-C2 
cells. 
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Table S2-1. Arid1a CNVs across Chaos3 MTs and controls determined by 
ddPCR. 
 
Sample
FAM 
(Arid1a )
HEX 
(Gapdh )
FAM 
(Arid1a )
HEX 
(Gapdh )
R1 
(FAM/HEX)
R2 
(FAM/HEX)
FAM 
(Arid1a )
HEX 
(Gapdh )
FAM 
(Arid1a )
HEX 
(Gapdh )
R1 
(FAM/HEX)
R2 
(FAM/HEX)
18333 F1 MT 266 260 264 263 1.0 1.0 1.0 370 698 283 545 0.5 0.5 0.5
16898 F1 MT 345 624 455 835 0.6 0.5 0.5 381 719 398 743 0.5 0.5 0.5
18656 F2 MT 230 448 697 1257 0.5 0.6 0.5 275 501 388 728 0.5 0.5 0.5
16694 F2 MT 219 403 271 526 0.5 0.5 0.5 319 664 1396 2990 0.5 0.5 0.5
16815 F2 MT 150 141 147 154 1.1 1.0 1.0 154 154 134 138 1.0 1.0 1.0
20626 MT 46.3 55.4 29.9 61.5 0.8 0.5 0.7 26.2 48.9 28.2 53.4 0.5 0.5 0.5
20894 MT 500 580 664 802 0.9 0.8 0.8 618 672 1119 1204 0.9 0.9 0.9
20164 MT 96 148 88 152 0.6 0.6 0.6 83 146 114 212 0.6 0.5 0.6
20889 MT 526 541 593 624 1.0 1.0 1.0 684 725 800 824 0.9 1.0 1.0
20892 MT 567 974 371 606 0.6 0.6 0.6 1158 1962 772 1327 0.6 0.6 0.6
20138 MT 660 1190 724 1297 0.6 0.6 0.6 691 1264 1900 3570 0.5 0.5 0.5
19959 MT 586 1193 379 736 0.5 0.5 0.5 1787 3510 1369 2680 0.5 0.5 0.5
18224 MT 189 197 157 166 1.0 0.9 1.0 191 219 678 818 0.9 0.8 0.9
20337 MT 143 199 150 209 0.7 0.7 0.7 2189 3440 2160 3420 0.6 0.6 0.6
21809 MT 54.6 99 199 343 0.6 0.6 0.6 670 1240 1267 2640 0.5 0.5 0.5
21038 MT 920 1625 1056 1912 0.6 0.6 0.6 2960 2920 2740 4580 1.0 0.6 0.8
21333 MT 84 101 112 128 0.8 0.9 0.9 1007 1222 1046 1276 0.8 0.8 0.8
22420 MT 548 668 621 787 0.8 0.8 0.8 523 811 573 887 0.6 0.6 0.6
21041 MT 41.6 40 28.2 32.7 1.0 0.9 1.0 363 518 1072 1522 0.7 0.7 0.7
21419 MT 120 145 75.4 99 0.8 0.8 0.8 1160 1770 986 1536 0.7 0.6 0.6
20459 MT 208 157 217 151 1.3 1.4 1.4 2700 2600 3070 3010 1.0 1.0 1.0
22476 MT 1026 1368 1144 1497 0.8 0.8 0.8 1110 1840 1596 2650 0.6 0.6 0.6
22180 MT 256 222 574 474 1.2 1.2 1.2 2630 2670 1989 2234 1.0 0.9 0.9
19660 MT 26.3 29.3 6330 11300 0.9 0.6 0.7 3370 3410 4100 4060 1.0 1.0 1.0
22238 MT 75.8 114 860 1337 0.7 0.6 0.7 1160 2090 1056 2020 0.6 0.5 0.5
22417 MT 132 109 155 124 1.2 1.3 1.2 204 238 137 165 0.9 0.8 0.8
21416 MT 756 919 917 1097 0.8 0.8 0.8 2043 2700 - - 0.8 - 0.8
20890 MT 13.4 18.5 629 872 0.7 0.7 0.7 577 984 - - 0.6 - 0.6
22235 MT 41.4 189 44.9 204 0.2 0.2 0.2 113 725 - - 0.2 - 0.2
20163 MT 544 421 471 373 1.3 1.3 1.3 1330 1650 - - 0.8 - 0.8
22414 MT 609 456 647 490 1.3 1.3 1.3 307 577 659 1333 0.5 0.5 0.5
22182 MT 88 88 280 268 1.0 1.0 1.0 690 810 1419 1685 0.9 0.8 0.8
21039 MT 1545 1912 839 1189 0.8 0.7 0.8 818 1514 - - 0.5 - 0.5
21124 MT 157 199 260 347 0.8 0.7 0.8 702 1251 1354 2403 0.6 0.6 0.6
21597 MT 162 206 305 388 0.8 0.8 0.8 1764 2880 1772 2960 0.6 0.6 0.6
20318 MT 186 243 289 365 0.8 0.8 0.8 231 375 216 399 0.6 0.5 0.6
22416 MT 220 185 132 124 1.2 1.1 1.1 80 82 119 133 1.0 0.9 0.9
21810 MT 291 424 340 505 0.7 0.7 0.7 368 574 2016 3640 0.6 0.6 0.6
21255 MT 516 653 921 1126 0.8 0.8 0.8 1220 1900 534 871 0.6 0.6 0.6
21254 MT 110 125 159 194 0.9 0.8 0.8 729 1154 151 241 0.6 0.6 0.6
22418 MT 214 303 486 678 0.7 0.7 0.7 1193 2162 1251 2376 0.6 0.5 0.5
21417 MT 51.7 49.4 170 167 1.0 1.0 1.0 713 812 1111 1281 0.9 0.9 0.9
21809 MT 10.6 16.6 319 394 0.6 0.8 0.7 1620 1570 468 773 1.0 0.6 0.8
21123 MT 101 127 106 138 0.8 0.8 0.8 2600 4550 1851 3030 0.6 0.6 0.6
21811 MT 240 279 299 349 0.9 0.9 0.9 1718 2510 267 388 0.7 0.7 0.7
22166 MT 182 216 107 130 0.8 0.8 0.8 1087 1655 1517 2329 0.7 0.7 0.7
20724 UT 446 408 437 418 1.1 1.0 1.1 404 396 507 513 1.0 1.0 1.0
17651 UT 119 99 105 91 1.2 1.2 1.2 104 108 100 99 1.0 1.0 1.0
17320 BT 90 89 89 91 1.0 1.0 1.0 91 86 105 107 1.1 1.0 1.0
C3H Ref DNA 76 68.1 98 99 1.1 1.0 1.1 47 48 38 40 1.0 1.0 1.0
B6 Ref DNA 1192 1199 835 870 1.0 1.0 1.0 456 506 515 541 0.9 1.0 0.9
C3H + B6 Ref DNA 329 311 177 175 1.1 1.0 1.0 109 108 93 101 1.0 0.9 1.0
20212 MT CL 187 225 213 244 0.8 0.9 0.9 491 566 345 399 0.9 0.9 0.9
21040 MT CL 889 1024 1165 1350 0.9 0.9 0.9 5340 6140 - - 0.9 - 0.9
21253 MT CL 4060 4040 755 776 1.0 1.0 1.0 2770 2780 2810 3430 1.0 0.8 0.9
22168 MT CL 1491 2066 2460 3590 0.7 0.7 0.7 2640 3910 2870 4860 0.7 0.6 0.6
23116 MT CL 1511 2610 1407 2410 0.6 0.6 0.6 No Call No Call 2760 5290 - 0.5 0.5
MCN1 1597 2530 - - 0.6 - 0.6 1251 2340 - - 0.5 - 0.5
C3H-Chaos3  Non-MT Controls
WT Reference Controls
Chaos3  and non-Chaos3  MT Cell Lines
Arid1a  Primer + Probe Set #1 Arid1a  Primer + Probe Set #2
R1 (copies/ul) R2 (copies/ul) RATIO R1 (copies/ul) R2 (copies/ul) RATIO
Avg.                 
(R1 & R2)
Avg.                  
(R1 & R2)
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Table S2-2. Comparison of Arid1a CNVs and expression across individual 
Chaos3 MTs. 
 
 
 
 
Sample ddPCR Probe 1 ddPCR Probe 2
Deletion Status of 
Arid1a
Relative Arid1a 
Expression
20724 UT 1.1 1.0 ND 1.0
17651 UT 1.0 1.0 ND 1.0
20889 MT 1.0 1.0 ND 0.8
20459 MT 1.4 1.0 ND 0.4
20212 MT CL 0.9 0.9 ND 0.7
21040 MT CL 0.9 0.9 ND 0.5
21253 MT CL 1.0 0.9 ND 0.4
18333 F1 MT 1.0 0.5 het deleted 0.2
16898 F1 MT 0.5 0.5 het deleted 0.04
16694 F2 MT 0.5 0.5 het deleted 0.1
20164 MT 0.6 0.6 het deleted 0.2
19959 MT 0.5 0.5 het deleted 0.2
21890 MT 0.6 0.5 het deleted 0.4
21038 MT 0.6 0.8 het deleted 0.03
22420 MT 0.8 0.6 het deleted 0.003
21041 MT 1.0 0.7 het deleted 0.5
19660 MT 0.7 1.0 het deleted 0.5
22238 MT 0.7 0.5 het deleted 0.1
20890 MT 0.7 0.6 het deleted 0.2
20163 MT 1.3 0.8 het deleted 0.3
21039 MT 0.8 0.5 het deleted 0.2
20318 MT 0.8 0.6 het deleted 0.2
21810 MT 0.7 0.6 het deleted 0.3
21809 MT 0.7 0.8 het deleted 0.3
21123 MT 0.8 0.6 het deleted 0.1
21811 MT 0.9 0.7 het deleted 0.4
22166 MT 0.8 0.7 het deleted 0.1
22168 MT CL 0.7 0.6 het deleted 0.2
23116 MT CL 0.6 0.5 het deleted 0.2
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Table S2-3. Primer Sequences. 
 
 
 
 
 
 
 
 
 
 
 
 
Gene Purpose Forward Primer Probe Reverse Primer
Arid1a_DNA ddPCR GTTCAAGGAAGGCCTGAACT TGGCAGAGCCTATAAGCCTCCAGTAGTCGC AGTCTGGGCAGGAAAGAGTA
Arid1a_DNA ddPCR TGGATGTCCTGGAAGTCTGA ACCTGAAATTCACCTCCCCCTGCCTCCC ACCCACTTCTTTGCACCTAC
Gapdh_DNA ddPCR TCCCTCGAACTAAGGGGAAA GGGGAGCAGGGTGGAGAGCCCG TCCATCCTCCAGAAACCAGA
Arid1a_DNA SNP Genotyping  GAAGCCGCATCTTGTCTACT - GCAGGTTGGTTTGGTTCTTG
Arid1a_m_RNA qRT-PCR TCCCAGCAAACTGCCTATTC
-
CATATCTTCTTGCCCTCCCTTAC
Arid1a_h_RNA qRT-PCR CAGTACCTGCCTCGCACATA
-
GCCAGGAGACCAGACTTGAG
Cdkn1a qRT-PCR AAGTGTGCCGTTGTCTCTTCG
-
AGTCAAAGTTCCACCGTTCTCG
Serpinb2 qRT-PCR ACTTAATGGGCTTTATCCTTTCC
-
TGCGTCCTCAATCTCATCG
Igfbp2 qRT-PCR GGCGCGGGTACCTGTGAAAA
-
TCTCCTGCTGCTCGTTGTAG
Igfbp5 qRT-PCR CAAGCACACTCGCATT
-
CAGGTACACAGCACGG
Gapdh qRT-PCR CTTTGTCAAGCTCATTTCCTGG - TCTTGCTCAGTGTCCTTGC
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Transcriptional Targets of Arid1a Tumor Suppression 
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One Sentence Summary: Potential transcriptional targets of Arid1a are identified in 
Chaos3 MT cells, through overlapping RNA-sequencing and ATAC-sequencing 
datasets. 
 
 
 
 
 47 
 
3.1 Abstract 
ARID1A encodes a mutually exclusive (with ARID1B) component of the 
mammalian SWI/SNF (BAF) chromatin remodeling complex. Recent cancer genome 
screens have identified mutations/alterations in multiple mSWI/SNF components 
across a spectrum of cancer types, with the highest frequency of mutations/alterations 
occurring in ARID1A. Multiple studies since have shown that ARID1A functions as a 
bona fide tumor suppressor, using different models for carcinogenesis. These studies 
have revealed the various pathways in which ARID1A plays a regulatory role, such as 
the PI3K/AKT, TP53 and TGFß signaling pathways, suggestively in a tissue-specific 
manner. Here, we attempted to identify genes that are direct transcriptional targets of 
Arid1a in the context of mammary tumorigenesis, using an in vitro system derived 
from a mouse model for sporadic breast cancer, in which Arid1a is recurrently deleted. 
By overlapping datasets generated from RNA-seq and ATAC-seq experiments 
conducted using Chaos3 MT cells overexpressing Arid1a, we identified a significant 
subset of genes that are both differentially expressed and correspond to increased 
“chromatin accessible” peaks upon overexpressing Arid1a. Amongst these, the most 
differentially up or down regulated (log2fold ≥ or ≤ 5) included several known 
cancer-associate genes that have previously not been associated with ARID1A 
molecular function, and thus could be potential novel targets of ARID1A 
transcriptional regulation. 
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3.2 Introduction 
Since the beginning of 2010, TCGA has revealed several novel candidate 
genes that may potentially play a causative role in carcinogenesis, based on their 
frequency of alteration in different types of human cancers. Amongst these, the genes 
encoding subunits of the mSWI/SNF complex were identified as the most highly 
mutated out of all the ATP-dependent chromatin remodelers1. The mSWI/SNF 
complexes are essential in regulating genetic programs and signaling pathways 
controlling replication, transcription, damage repair, differentiation, migration and 
development, amongst others2,3. The broad range of function and extensive cancer 
mutation spectrum of these complexes suggests that they play a widespread role in 
tumor suppression by protecting fundamental cellular activity and survival. 
ARID1A (BAF250a, SMARCF1, p270) is a component of the BRG1-
associated factor (BAF) complex, which is a subfamily of the SWI/SNF chromatin 
remodelers. Its paralog, ARID1B, appears to be differentially expressed in embryonic 
tissues, suggesting these mutual exclusive proteins may confer target and lineage 
specificity to the BAF complexes during development4,5. Additionally, ARID1A and 
ARID1B demonstrate nonsynchronous kinetics during cell cycle progression and 
appear to bind different transcriptional targets under normal circumstances5-7. A recent 
screen for targets that conferred synthetic lethality to ARID1A mutant cell lines 
identified ARID1B as its top hit, and showed that it is required for stable assembly of 
the BAF complexes in ARID1A-deficient cells8. 
ARID1A contains a highly conserved DNA-binding domain called ARID (AT-
rich interactive domain) that spans approximately 100 amino acids of the protein. 
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Although ARID domains in general bind AT-rich sequences preferentially, it has been 
shown that mammalian ARID1A binds DNA without sequence specificity9,10. 
Disruption of ARID1A-DNA binding has been found to result in embryonic lethality 
in mice, due to impaired nucleosome substrate binding and promoter occupancy by 
mutant ARID1A-containing mSWI/SNF complexes6.  
ARID1A is the most frequently altered SWI/SNF subunit in cancer, with 
inactivating mutations/deletions occurring in a spectrum of tumor types. Despite all 
the evidence pointing towards an important tumor suppressive role in various cancers, 
the exact mechanism by which ARID1A prevents tumor growth in different tissue 
contexts is still unclear. Functional studies using different model systems have shown 
that ARID1A may behave as both a “gatekeeper” and a “caretaker” tumor suppressor, 
as it plays essential roles in cell cycle regulation and DNA damage repair, 
respectively11. Studies using GEMMs for cancer in which ARID1A has been 
conditionally deleted or mutated within specific tissues have revealed 
crosstalk/collaboration with different signaling pathways, including PI3K/AKT and 
TP5312-14. 
Mechanistically, ARID1A is thought to regulate gene function in two ways – 
(1) by facilitating the recruitment of BAF complexes to DNA regulatory elements 
through interaction with other transcription factors/cofactors (2) by direct 
transcriptional regulation of specific targets through its interaction with histone-
modifying enzymes15. In my research work described in this chapter, I have attempted 
to differentiate between these direct and indirect targets of ARID1A transcriptional 
regulation by overlapping datasets derived from transcriptome sequencing and ATAC 
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(Assay for Transposase-Accessible Chromatin) sequencing, using a Chaos3 MT cell 
line in which Arid1a has been ectopically overexpressed16. 
 
3.3 Results 
Mapping of open chromatin following Arid1a overexpression  
I followed the experimental scheme outlined in Figure 3-1A, with the goal of 
correlating mapped regions of open chromatin with differential gene expression. 
Mouse MT cells representing the untransduced (UT) and the add-back (AB) with low 
and high Arid1a levels, respectively, were dispersed into single cell suspensions and 
subjected to barcoding following integration of the Tn5 transposase bearing 
sequencing adapters.  Based on the principle of transposase activity, only open/easily 
accessible chromatin regions will be targeted for sequencing, and not tightly 
packed/closed genomic regions17. The ATAC-seq libraries generated by each sample 
replicate produced the expected distribution of fragment lengths, with the majority 
representing smaller fragments of open inter-nucleosome regions, and very few 
representing larger fragments spanning intact/positioned nucleosomes, as has been 
previously described18.  
Approximately 70% of ATAC-seq peaks identified in the UT (control) 
replicates were also present in the AB (experimental) replicates, but expectedly there 
was a significant increase in the number of ATAC-seq peaks in the AB cells as a 
direct consequence of overexpressing Arid1a, with 13,536 AB-specific peaks detected 
compared to only 4,968 UT-specific peaks detected (Figure 3-1B). 
 51 
 
Annotation of ATAC-seq peaks revealed that overexpressing Arid1a in the 
Chaos3 MT cells resulted in a two-fold increase in the number of peaks associated 
with the transcription start sites (TSS) and 5’ untranslated region (5’ UTR) regions of 
genes (Figure 3-1C), suggestive of a dramatic increase in gene transcriptional activity 
attributed directly to Arid1a function. 
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Figure 3-1. ATAC-seq peaks identified in Chaos3 MT cells overexpressing 
Arid1a. (A) Schematic outline of experiment to determine direct transcriptional targets 
of ARID1A. (B) Venn diagram indicating the numbers of ATAC-seq peaks identified 
in untransduced (UT) and Arid1a add-back (AB) MT cells. (C) Pie charts representing 
annotation of UT-specific and AB-specific peaks. 3’ UTR = 3’ Untranslated region; 5’ 
UTR = 5’ Untranslated region; Promoter-TSS =Promoter transcriptional start site; 
TTS = Translational termination site 
B C 
A 
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Integration of ATAC-seq and RNA-seq results in tumor cells overexpressing Arid1a 
In previously published work, I have conducted mRNA-sequencing 
experiments to identified genes that are differentially expressed (DE) upon ectopic 
introduction of Arid1a in mouse mammary tumor cells that are hemizygously deleted 
for it16. Pathway analyses of the DE genes revealed alterations in critical growth and 
proliferation pathways, including TGF Beta and TP53. While this experiment was 
useful for identifying potential targets of Arid1a regulation, it is not sufficient on its 
own to differentiate between those that are direct or indirect. 
To determine whether open regions of chromatin correlated with gene 
expression changes, we integrated the ATAC-seq and RNA-seq datasets to identify 
overlapping genes. Of the 1,064 DE genes identified by RNA-seq (UT cells vs. AB 
cells) previously, we found that 593 genes (~56 %) corresponded to annotated open 
chromatin regions identified by ATAC-seq (AB cell-specific peaks) (Figure 3-2A). 
The overall representation of annotated peaks did not vary significantly between the 
AB-specific ATAC-seq peak data and the overlapping DE gene set (Figure 3-2B). 
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Figure 3-2. Overlapping Gene Set Representing Direct Transcriptional Targets of 
Arid1a. (A) Venn diagram showing the number of overlapping genes in the ATAC-
seq and RNA-Seq datasets. (B) Pie charts showing annotation of ATAC-seq peaks and 
overlapping peaks with RNA-seq DE genes. 3’ UTR = 3’ Utranslated region; 5’ UTR 
= 5’ Untranslated region; Promoter-TSS =Promoter transcriptional start site; TTS = 
Translational termination site. 
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Genes Identified as Direct transcriptional targets of Arid1a 
To further narrow down the integrated RNA-seq and ATAC-seq data to 
potential direct transcriptional targets of Arid1a, we identified the most highly 
differentially expressed genes within the overlapping dataset (≥ or ≤ 5 Log2 fold 
expression; RPKM >5). This resulted in a list of 25 gene transcripts (Table 1). Several 
of these genes (9/25) had peaks located within 1Kb of the TSS, and an equal number 
(9/25) had more than one type of annotated peak, suggesting multiple access points for 
ARID1A binding at those genes. 
Amongst this set of transcripts are three genes encoding type 1 collagen 
(Col23a1, Col1a1 and Col1a2), which are a group of transmembrane proteins 
representing a major component of the extracellular matrix (ECM), whose expression 
is controlled in a tissue-specific manner during normal development and 
carcinogenesis19. COL23A1 was first identified as a biomarker in metastatic tumor 
cells20, and is a biomarker for detecting recurrent non-small cell lung and prostrate 
cancer21,22.  Abnormal COL1A1 and COL2A1 expression has been identified in breast 
cancer23-28, renal cancer29, hepatocellular cancer30, melanoma31 and gastric cancer32. 
Also included are genes encoding multiple growth factor and growth factor 
receptor proteins, namely fibroblast growth factor receptor 2 (Fgfr2), insulin-like 
growth factor receptor (Igf1), multiple epidermal growth factor-like domains protein 6 
(Megf6) and nerve growth factor receptor (Ngfr). FGFR signaling is important for both 
embryonic development and adult tissue homeostasis, and is found to be dysregulated 
in a variety of human cancers33, including breast23,34. IGF1 signaling also plays a 
critical role in development and carcinogenesis, particularly with respect to hormone-
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sensitive cancers such a breast, ovarian, endometrial and pancreatic carcinomas35-38. 
Finally, NGFR is a prognostic marker for luminal subtypes of breast cancer39, as well 
as many other cancer types40-42, and has been identified as a transcriptional target of 
TP5343. 
Other interesting genes from the list included chordin-like 1 (Chrdl1), which 
encodes an antagonist of bone morphogenic protein 4 (Bmp4) and has been recently 
identified as a tumor suppressor in breast cancer44,45, gastric cancer46, lung cancer47 
and melanoma48. C-X-C chemokine receptor type 4 (Cxcr4) is a G-protein coupled 
receptor that has been well characterized as an oncogenic factor in more than 23 
different human cancers, and is considered an important target for therapeutic 
intervention49. Plasminogen activator inhibitor-1 (Pai1/Serpine1) encodes a member 
of the plasminogen-plasmin system that plays a critical role in cell migration, cell 
proliferation and tissue remodeling, and has been implicated as a valuable prognostic 
indicator in a spectrum of cancer types50, particularly in breast cancer50,51. Semaphorin 
4D (Sema4D) encodes a member of the semaphorin family of secreted membrane 
proteins, that has been shown to function as a potent oncogene and metastatic factor in 
breast cancer52,53, as well as playing a prognostic role in several other cancer types54-57. 
Cellular retinoic acid-binding protein 1 (Crabp1) plays a key role in tumor response to 
retinoic acid and is often hypermethylated in cancer, with its low expression serving as 
a poor prognosis indicator in multiple cancer types58-62, particularly in breast cancer63. 
Pituitary Tumor Transforming Gene 1 (Ptt1) behaves as an oncogene in a variety of 
endocrine and non-endocrine cancers64, and was found to promote tumor cell growth 
by inhibiting TGFß1/SMAD3 signaling in breast, prostate and lung cancers65-67. 
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Alpha-smooth muscle actin (Acta2) is a stromal biomarker of cancer-associated 
fibroblasts68,69, and its increased expression is associated with accelerated invasiveness 
and metastasis of breast cancer cells70. Ras homolog gene family, member C (RhoC) 
encodes a small signaling GTPase, and behaves as a potent oncogenic factor in several 
different cancer types, including breast cancer71-78. Dickkopf WNT Signaling Pathway 
Inhibitor 2 (Dkk2) encodes a protein that is involved in embryonic development 
through its interactions with the Wnt signaling pathway, and is frequently 
dysregulated in several different cancer types79-84. Finally, Small Nuclear 
Ribonucleoprotein Polypeptide N (Snrpn) encodes a protein that plays a role in pre-
mRNA processing and tissue-specific alternative splicing events, and appears to 
behave as an oncogenic factor in medulloblastomas and pancreatic cancer85,86. The 
cancer-associated roles of these genes have been summarized in Table 3-2. 
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Table 3-1. Potential direct transcriptional targets of Arid1a gene regulation. 
Highest DE genes (≥ or ≤ 5 Log2 fold expression; RPKM >5) present within the 
overlap dataset. X= presence of annotated peaks from ATAC-seq dataset. 
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Table 3-2. Cancer-specific associations of genes present within overlap dataset. 
Cancer-specific associations of highest DE genes (≥ or ≤ 5 Log2 fold expression; 
RPKM >5) present within the overlap dataset. 
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3.4 Discussion  
In this chapter, I have described an experimental approach to determine direct 
transcriptional targets of Arid1a gene regulation, using a previously published in vitro 
model system of mammary tumor cells in which Arid1a is ectopically 
overexpressed16. By comparing ATAC-seq and RNA-seq profiles, we generated an 
overlapping dataset of annotated genes that (a) correspond to open chromatin regions 
and (b) are differentially expressed, both as a direct result of overexpressing Arid1a in 
these tumor cells. While RNA-sequencing reveals the differential abundance of global 
mRNA transcripts upon overexpressing Arid1a, ATAC-sequencing measures genome-
wide differences in chromatin accessibility within the same context. Thus, the 
overlapping dataset represents open chromatin regions that also correspond to 
differentially expressed genes, and serves as a proxy for direct transcriptional gene 
regulation by Arid1a.  
Amongst the most differentially expressed (both upregulated and 
downregulated) genes present in the overlapping dataset, several of them were found 
to be cancer-associated genes that have well established roles in human 
carcinogenesis. More important and relevant to my research question, some of these 
cancer-associated genes are also known to be associated with SWI/SNF activity. Fgfr2 
has been found to be upregulated in human fibroblasts with impaired mSWI/SNF 
function, and has been proposed as a therapeutic target in SNF5 (SMARCB1)-deleted 
malignant rhabdoid tumors87. Reduced expression of Igf1 has been found to occur in 
BRG1 (SMARCA4)-depleted melanoma cells, and restoring its expression in these 
cells is sufficient to relieve the stalled cell proliferation imposed by BRG1 depletion88. 
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Cxcr4 has been found to be dysregulated in the context of SNF5-deficient atypical 
teratoid/ rhabdoid (aggressive brain) tumors89. In a drosophila model system, Col1a2 
transcription has been shown to be regulated by TGFß-induced chromatin remodeling, 
brought about by the SWI/SNF complex90. Finally, chromatin immunoprecipitation of 
BRG1 in embryonic stem cells showed localized mSWI/SNF binding near the Crabp1 
promoter, and its expression was found to be decreased upon RNAi targeting of 
BRG1, suggesting that Crabp1 is under the direct transcriptional control of BRG1-
containing mSWI/SNF complexes91. To date, none of these genes have been 
implicated directly with ARID1A gene regulation, either independently or within its 
context of mSWI/SNF activity. We propose that they may be novel targets of ARID1A 
regulation based on the significant correlation of chromatin accessibility and 
differential gene expression. Follow-up experiments validating the physical binding of 
ARID1A at these specific genetic loci, as well as functional validation of target gene 
activity upon further perturbation of Arid1a expression in this in vitro model system 
would be necessary to unequivocally conclude that they are indeed transcriptional 
targets of Arid1a gene regulation.  
 
3.5 Methods 
ATAC Sequencing Library Preparation 
Homogenous, single-cell suspensions of both control (untransduced) and 
experimental (Arid1a add-back) samples were generated using 75,000 cells/sample. 
Cells were centrifuged and lysis buffer (10 mM Tris·Cl, pH 7.4; 10mM NaCl; 3mM 
MgCl2; 0.1% (v/v) Igepal CA-630) was added to them. Following lysis, cells were 
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treated with TDE1 ((Nextera Tn5 Transposase from Nextera kit; Illumina, cat. no. FC-
121-1030). The transposition reaction was carried out at 37C for 30 mins. Following 
transposase treatment, DNA was purified using the Qiagen MinElute PCR Purification 
Kit. Purified DNA was eluted in 10ul Buffer EB. Purified DNA was amplified via 
PCR in 10 cycles, using barcoded primers described in Supplementary Table 1. 
Amplified DNA was re-purified using the Qiagen MinElute PCR Purification Kit, and 
eluted in 20ul Buffer EB. Quality of purified DNA was checked by Bioanalyzer High-
Sensitivity DNA Analysis kit (Agilent), and quantification was done using Qubit 
Fluorophore. Replicate libraries were prepared for both control and experimental 
samples. All libraries were sequenced on the Illumina HiSeq 2500 with 50bp single-
end reads. Approximately 50 million reads were generated/library.  
 
ATAC Sequencing Analysis 
Base calling and initial data processing were performed using the standard 
Illumina protocol.  Reads quality control check was investigated by FastQC 
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc/). Adapter was removed by 
software trimmomatic92. The reads were aligned to mouse reference genome sequence 
(mm10) using the bowtie2 (2.3.0) aligner93 with ’--local’ option specified. Duplicates 
were removed using Picard and mapping quality of >10 were retained. The peak-
calling was done by the ENCODE ATAC-seq pipeline 
(https://www.encodeproject.org/atac-seq/), with mapping quality parameter >10. 
Significant and reproducible ATAC-seq peaks produced by Irreproducible Discovery 
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Rate (IDR) were used for downstream analysis. The peaks overlapped genome 
features were performed by annotatepeaks.pl function from HOMER94. 
 
RNA Sequencing 
RNA-seq data used for determining the overlapping gene dataset was 
generated previously in my published research16.  
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One Sentence Summary: Endogenous activation of intact Arid1a allele in 
heterozygously deleted Chaos3 MT cell line results in reduced proliferation and 
colony formation rates. 
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4.1 Abstract 
The chromatin remodeling component ARID1A has been recently identified as 
being altered at high frequencies across a spectrum on human tumor types. It is now 
recognized as a bona fide tumor suppressor gene, based on experiments conducted in 
different model systems, both in vitro and in vivo. Interestingly, ARID1A is 
heterozygously deleted in a substantial fraction of human tumors. In our mouse model 
for sporadic breast cancer, we have found that the majority of mammary tumors also 
bear heterozygous deletions of Arid1a, and have shown that this monoallelic deletion 
correlates with expressed transcript levels of the gene. While canonically, tumor 
suppressor genes (TSGs) are thought to behave in a recessive manner, requiring 
biallelic loss of function to drive carcinogenesis, it is now becoming clear that certain 
TSGs can in fact behave in a haploinsufficient manner, with dosage levels playing a 
critical role in certain types of cancer. In this chapter, I aimed to address the question 
of whether ARID1A may behave as a haploinsufficient tumor suppressor gene in the 
context of certain tissue backgrounds and tumor types, particularly focusing on a 
mammary tumor cell line in which one intact allele of Arid1a remains expressed. 
Using a CRISPR/dCas9-based technique for locus-specific activation of gene 
expression, I was able to endogenously induce Arid1a expression to biallelic levels in 
these tumor cells, and found that it was sufficient to significantly reduce the rate of 
proliferation and colony formation, suggestive of the importance of dosage levels in 
Arid1a’s tumor suppressive activity. 
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4.2 Introduction 
Sporadic breast cancer (i.e., not associated with inherited neoplasia-driving 
mutations) accounts for the vast majority of breast cancer cases worldwide (80-85%). 
Such cancers arise from multiple spontaneous genetic mutations and/or epigenetic 
modifications, and it is important to be able to differentiate between those that drive 
cancer formation and those that are a by-product of it. ARID1A, encoding an important 
component of the mammalian SWI/SNF complex, has emerged as one of the most 
commonly mutated or downregulated genes in diverse cancer types1-8, including breast 
cancer9,10. ARID1A impacts epigenetic gene regulation by altering chromatin structure 
around promoters of specific loci in conjunction with its associated SWI/SNF complex 
components11,12. Therefore, its downregulation or mutation in somatic cells can have 
profound consequences, including inappropriate proliferation13.  
TCGA data has revealed that the majority of cancer-associated alterations in 
ARID1A are inactivating by nature, with either nonsense/frameshift mutations or 
partial/whole gene deletions detected, based predominantly on tumor type14.  Most 
interestingly, a significant number of these tumor mutations/deletions appear to be 
heterozygous, i.e. affecting a single allele, with detectable protein expression present 
in ovarian clear cell, gastric, hepatocellular and breast carcinomas10,15-18. These 
observations lead to the hypothesis that ARID1A is recurrently mutated/deleted in one 
allele, but expressed by the remaining allele, thereby suggesting that ARID1A levels 
may facilitate a haploinsufficient effect during carcinogenesis. 
While canonically, TSGs were thought to behave according to Knudson’s two-
hit hypothesis19, it is now widely accepted that certain TSGs, including TP53 and 
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PTEN, can behave in a much more potent manner, with even partial inactivation 
critically contributing to tumor growth/maintenance20-22. There are multiple studies 
that support a haploinsufficient role for ARID1A. In breast cancer, two independent 
studies have found that ARID1A haploinsufficiency correlates significantly with 
higher risk and poorer prognosis10,23. In vitro, partial knock-down of ARID1A 
expression in different cell types results in increased proliferation and colony 
formation10,23-25, decreased apoptosis26 and impaired differentiation25,27. In vivo, 
Arid1a haploinsufficiency in mice has been found to lead to incomplete embryonic 
development27, necessitating the use of conditional knock-out models to study the 
consequence of complete loss of ARID1A function in specific tissues. This in itself 
suggests a critical dosage effect of Arid1a during development and differentiation, 
which could potentially translate to carcinogenesis as well.  
In my work described in this chapter, I attempt to address this question of 
whether Arid1a may behave as a haploinsufficient TSG using a mammary tumor cell 
line derived from our lab’s mouse model for sporadic breast cancer (the Chaos3 
mouse model), which is heterozygously deleted for Arid1a, with the remaining intact 
allele still expressing it. I have used a CRISPR-based approach to restore expression 
of Arid1a to wild-type (WT) levels via endogenous induction at its promoter. This 
resulted in a reduced rate of colony formation and proliferation in vitro. 
 
 
 
 
 74 
 
4.3 Results 
Endogenous induction of Arid1a using Synergistic Activation Mediators 
To endogenously induce expression of Arid1a, I used a CRISPR/dCAS9 – 
based transcription activation system called Synergistic Activation Mediators (SAM), 
developed by Konermann et al.28. This method involves the locus-specific activation 
of gene expression via three main components – (1) a deactivated/dead Cas9 (dCas9) 
protein fused with a transactivating domain (VP64) (2) MS2 aptamers fused with 
additional activating co-factors (HSF1 and p65) and (3) a locus-specific small guide 
RNA (sgRNA) incorporated with MS2 aptamers. Together, when these components 
are transduced into the target cells, the sgRNA will guide the activating factors 
(dCas9-VP64 and MS2-p65-HSF1) to the promoter of the targeted gene and induce 
transcriptional activation (Figure 4-1A). Here, I have used an in vitro system 
consisting of a mammary tumor cell line (23116 MT) derived from the Chaos3 mouse 
model which is hemizygously deleted for Arid1a, but retains expression of the 
remaining intact allele.  
But first, I needed to evaluate the efficiency of candidate sgRNAs targeting the 
Arid1a promoter locus. I selected 8 sgRNAs spread across the proximal promoter of 
Arid1a, all within 200 base pairs of the transcription start site (TSS) (Figure 4-1B). 
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Figure 4-1. Arid1a induction using synergistic activation mediators (SAM).  
(A) Outline of SAM induction at Arid1a promoter in Chaos3 MT cell line 23116 MT. 
(B) Genomic locations on UCSC browser of candidate small guides (sg) tested. 
Arrows indicate direction of gene transcription. 
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Determining Efficient Candidate Guides for Arid1a Induction 
Efficient induction of Arid1a expression was determined by testing eight 
different candidate sgRNAs targeting the Arid1a promoter. 23116 MT cells were first 
co-transduced with the SAM activating factors, and successfully integrated cells were 
then transduced with individual guides. Following drug selection, the candidate guides 
were assayed for efficient induction of Arid1a by comparing the rate of colony growth 
(Figure 4-2A). Successful induction on Arid1a expression in the tumor cells would 
expectedly result in either smaller or fewer colonies formed following selective 
growth. Small guides (sg) 1 and 5 were the most consistently effective at producing 
smaller/fewer colonies following SAM transduction and selection, relative to the two 
non-targeting controls (NTCs) (Figure 4-2B). 
Next, to confirm that the clonogenic assay phenotype was indeed due to 
activation of Arid1a expression, I picked individual colonies from the two 
representative candidate guides (sg1 and sg5) and the two NTCs and extracted mRNA 
to determine relative Arid1a transcript levels by quantitative real-time PCR (q-RT-
PCR). This revealed that of the two candidate guides, only sg5-transduced colonies 
were upregulated for Arid1a expression, on average approximately two-fold relative to 
the NTCs, whereas the sg1-transduced colonies were not, suggesting that the 
phenotype observed in that case was due to some off-target effect (Figure 4-2C). 
Based on these results, I decided to move forward with sg5 as the most efficient 
candidate guide for endogenous induction of Arid1a using SAM. 
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Figure 4-2. Candidate guides tested to determine induction efficiency.  
(A) Schematic outline of SAM transduction and clonogenic assay protocol. (B) 
Representative clonogenic assay comparing colony formation ability of 23116 MT 
cells transduced with different sgs; NTC = Non-targeting control; UTC = 
Untransduced control. (C) q-RT-PCRs quantifying Arid1a transcript levels in induced 
clonal cell lines and control cell lines; N=number of clonal lines analyzed. Error bars 
represent SEM. 
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Endogenous Induction of Arid1a Expression Significantly Reduces the Rate of Cell 
Proliferation 
Next, I wanted to confirm that the increased expression of Arid1a observed in 
the induced 23116 MT cells actually has an effect on the rate of cell proliferation. For 
this, I conducted a 5-day growth assay of three representative “induced” cell lines and 
“uninduced” control cell lines, transduced with sg5 or NTCs, respectively. The 
induced cell lines showed approximately twice the amount of Arid1a expression levels 
relative to the NTC cell lines (Figure 4-3A). The growth assay showed a significant 
decrease in the rate of proliferation of all three induced cell lines, compared to the 
NTC cell lines (Figure 4-3B), thus confirming that induced Arid1a expression to WT 
levels results in a decreased growth rate of cells in vitro.  
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Figure 4-3. Growth assays to determine proliferation rates of induced cell lines.  
(A) Arid1a mRNA transcript levels of clonal lines assayed for proliferation; Cn = 
clone number (B) Growth rates of induced and control cell lines over a period of five 
days. Error bars represent SEM. P value was calculated for averages between the two 
groups at final data point (Day 5).  
 
 
 81 
 
Confirming the Specificity of Arid1a induction by SAM 
To confirm that the observed reduction in growth in 23116 MT cells following 
SAM transduction with sg5 was indeed a direct result of endogenous activation of 
Arid1a expression, I used siRNAs targeting Arid1a to knock-down its expression in 
representative “induced” and “uninduced” control cell lines. The efficiency of Arid1a 
knock-down was approximately 40%, assessed via q-RT-PCR (Figure 4-4A). 
Knocking down Arid1a in the induced cells resulted in a significant increase in 
proliferation, confirming the reversal of the reduced growth phenotype in these cells, 
while there was no effect on the rate of proliferation in the uninduced control cells 
(Figure 4-4B). This experiment validates the specificity of endogenous Arid1a 
induction via SAM, using sg5 as a guide. 
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Figure 4-4. siRNA knock-down (KD) of Arid1a in induced clonal cell line to 
reverse reduced growth phenotype.  
Arid1a KD verification by (A) q-RT-PCR and (B) Cell growth assay following Arid1a 
siRNA KD in induced and control clonal cell lines. Error bars represent SEM. P value 
was calculated for averages of KD and control cell lines at final data point (Day 5). 
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4.4 Discussion 
In breast cancer studies, partial loss of ARID1A expression has been linked 
with advanced clinical stage and unfavorable outcomes in patients23,29,30. Additionally, 
a significant subset of human breast cancers is heterozygously deleted for ARID1A, 
suggestive of a haploinsufficient tumor suppressive role9,31,32. Mammary tumors that 
developed spontaneously in the Chaos3 mouse model for sporadic breast cancer were 
also found to bear mono-allelic deletions of Arid1a, and these deletions correlated 
with reduced Arid1a expression levels33.  
To determine whether Arid1a dosage was critical for tumor cell growth, I 
utilized an in vitro system consisting of a mammary tumor cell line derived from the 
Chaos3 mouse model, in which one copy of Arid1a was deleted, and expression levels 
were less than half relative to wild-type mammary tissue33. With the goal of returning 
Arid1a expression to biallelic levels in these tumor cells, I used a CRISPR/dCas9-
based activation system to epigenetically induce expression of the remaining intact 
Arid1a allele. Induced Arid1a expression levels were confirmed by q-RT-PCR. 
Phenotypic analyses of tumor cells in with restored Arid1a expression showed a 
decrease in cell proliferation and colony formation, signifying the importance of 
Arid1a dosage in regulating tumor cell growth. Previously, we have shown that 
ectopic overexpression of Arid1a in this same mammary tumor cell line resulted in the 
alteration of critical oncogenic and tumor suppressive pathways, including TGFß and 
TP53, and dramatically reduced cell proliferation and tumor growth rates33. It is 
possible that these same pathways are also being altered upon endogenous induction 
of the remaining Arid1a allele to wild-type expression levels, and follow-up 
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experiments such as whole transcriptome analyses in the Arid1a-induced cell lines 
would be necessary to further characterize this effect. 
Therapeutically, this would offer an opportunity for targeting subsets of human 
cancers that retain a single copy of ARID1A, by attempting to decrease tumor growth 
through endogenous induction of gene expression of this potent tumor suppressor. In 
my experiments, I utilized a CRISPR/dCas9-based system to endogenously activate 
Arid1a expression and slow down proliferation in mammary tumor cells. Several 
recent proof-of-principal studies have used similar CRISPR-based techniques to 
directly alter tumor genomes in vivo using mouse models34-39. While there are current 
technical limitations to directly applying such technology in gene therapy for cancer 
patients, rapid advancements in improving this technology will likely increase the 
efficiency of delivery of CRISPR- Cas9/dCas9 components, ultimately allowing for 
the therapeutic alteration of expression for single or multiple cancer driver genes40-42. 
Studies conducted thus far in the year 2017 have successfully used artificial viruses, 
synthetic nanoparticles and combination viral and non-viral delivery of CRISPR-Cas9 
components for efficient gene targeting in both cells and mouse models of disease43-45. 
The ultimate goal will be to help usher in the era of personalized cancer treatment by 
using advanced technological approaches to (1) identify modifiable genetic/epigenetic 
alterations in individual patient tumors, (2) characterize the driver alterations and 
differentiate them from potential passenger alterations and (3) specifically edit cancer 
genomes by targeting these driver oncogenes and tumor suppressors to regress/halt 
tumor growth with minimal side-effects. 
 
 85 
 
4.5 Materials and Methods 
SAM Plasmids 
SAM effector plasmids (dCas9-effector and MS2-effector) and sgRNA 
backbone plasmid were obtained from Addgene (#61425, # 61426 and #61427). The 
small guide sequences targeting the Arid1a promoter were designed using the 
bioinformatic tool developed by Feng Zhang’s lab (http://sam.genome-
engineering.org/database/). Individual sgRNA sequences and non-targeting control 
sequences (NTCs) were cloned into the empty backbone vector (Addgene #61427) by 
golden gate assembly, and successful clones were verified by Sanger sequencing. 
 
SAM Lentivirus Production 
HEK293T cells were cultured in high-glucose DMEM (Life Technologies), 
supplemented with 10% fetal bovine serum (Gemini Bio Products), 1% 
penicillin/streptomycin and sodium pyruvate (Life Technologies). For generating 
SAM viruses, HEK293T cells were seeded in 10cm dishes at 40-60% confluency, and 
viral packaging plasmid pMD2.G (2.5ug), viral enveloping plasmid psPAX2 (7.5ug) 
and each SAM plasmid (10ug) were transfected together into the cells in media not 
containing any antibiotics. Twelve hours following transfection, viral media was 
replaced with 10ml fresh media and allowed to incubate for 48 hours at 37C. After 
this, the first round of virus was collected and stored at 4C. 5ml fresh media was 
added and cells were incubated for another 24 hours before second round of virus 
collection. 15 ml of virus was then concentrated by centrifugation in Amicon Ultra 
filtration columns (EMD Millipore), followed by additional filter sterilization of 
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concentrated virus using 0.45-um PVDF filters. Virus for each SAM component 
(dCas9-effector and MS2-effector), and each individual candidate sgRNA was 
generated independently.  
 
SAM Lentivirus Transduction and Selection 
23116 MT cells were cultured in complete medium described above. The day 
before virus transduction, 250,000 cells were seeded in 35mm cell culture dishes. The 
next day, freshly prepared and concentrated SAM-effector viruses (dCas9-effector and 
MS2-effector) were added to the cells and incubated overnight at 37C. The next 
morning, viral media was replaced with fresh media containing Blasticidin (9ug/ml) 
and Hygromycin (500ug/ml). Cells were incubated for ~1 week at 37C, under 
continuous drug selection. Resistant cells were pooled and used to transduce the 
individual sgRNAs targeting the Arid1a promoter region, to determine their 
efficiencies. 
 
Clonogenic Assays 
Pooled 23116 MT cells transduced with SAM-effectors were seeded in 6-well 
culture dishes at a density of 1000 cells/well. Fresh, concentrated virus generated for 8 
sgRNAs and 2 NTCs were added to individual wells. The next morning, viral media 
was removed and replaced with media containing Zeocin (1mg/ml). Cells were 
incubated at 37C for ~10 days under drug selection, allowing for the formation of 
colonies. To visualize the colonies formed, media was removed and each well was 
rinsed with PBS. 2ml/well fixation solution (3:1 methanol:acetic acid) was added and 
 87 
 
cells were incubated at room temperature (RT) for 10mins. Fixation solution was 
removed and 2ml/well crystal violet (HT90132 Sigma) staining solution was added 
and cells were incubated at RT for 30mins. Culture dishes were then immersed gently 
in tap water to rinse of staining solution completely, and then allowed to dry at RT. 
Colony formation was visualized and documented after scanning whole culture dishes 
and generating TIFF images. 
 
q-RT-PCR 
Total RNA was isolated from cells using the E.Z.N.A. Total RNAKit I (Omega 
Biotek). A total of 100 ng of RNA was used for cDNA synthesis using the qScript 
cDNA Supermix Kit (Quantabio). q-RT-PCR analyses was done using Fast SYBR 
Green Master Mix (Life Technologies) and custom designed primers (Table ) for 
detecting Arid1a transcript levels, using Gapdh as an endogenous housekeeping 
control. Assays were run on the CFX96 Touch Real-Time PCR Detection System 
(Bio-Rad). Each sample was run in triplicate wells, from which mean Ct values were 
obtained. Relative quantification of gene expression was calculated using the DDCt 
method. At least two technical replicates were run for each experiment to obtain 
standard error values. 
 
Cell Proliferation Assays 
Representative “induced” and “uninduced” cell lines were seeded in triplicate 
in 6-well culture dishes at a density of 20,000 cells/well. The next day, cells were 
washed with PBS and trypsinized, and counted using a hemocytometer. After cell 
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counts were recorded, the cells were re-seeded in fresh 6-well culture dishes and 
incubated at 37C. This protocol was repeated for the next four days (total growth assay 
time = five days). Standard error values were obtained from three experimental 
replicates.  
 
siRNA Transfection 
siRNAs targeting Arid1a and a non-targeting scramble control were obtained 
from Origene (# SR423286, Trilencer-27). siRNAs were first diluted to a stock 
concentration of 20uM in the duplex buffer provided. The day before transfection, 
representative “induced” and “uninduced” cell lines were seeded in 6-well culture 
dishes at a density of 20,000 cells/well and incubated at 37C. The next day, Arid1a 
and control siRNAs were further diluted to a working concentration of 50uM, and then 
transfection mixtures were set up for a single well as follows – 20ul siTRAN 1.0 
(Origene) +120ul Opti-MEM (Life Technologies) + 4ul siRNA (final concentration = 
10nM) + 2800ul culture media. Transfection mixtures were incubated at RT for 10 
mins before adding it dropwise to cells seeded in 6-well format. Cells were then 
incubated at 37C.  
For validating knock-down efficiency, cells were harvested 48 hours following 
transfection to assay Arid1a mRNA transcript levels by q-RT-PCR. Each siRNA 
reaction was carried out in triplicate to obtain standard error values. 
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CHAPTER 5 
Summary and Discussion 
 
5.1 Chromatin Remodelers in Cancer 
Eukaryotic chromatin consists of highly condensed structural units called 
nucleosomes, formed by the tight coiling of chromosomal DNA and histone proteins1. 
Chromatin remodeling proteins utilize ATP energy to mobilize nucleosomes, both by 
direct physical sliding as well as by indirect catalysis of the ejection/insertion of 
histones, thus mediating the access of DNA-binding proteins to double-stranded DNA 
in a locus-specific manner2-4. Chromatin remodeling proteins thus play important roles 
in several essential biological processes, including the regulation of cell division, gene 
expression, DNA repair, and lineage-specification4,5. Of these, the SWI/SNF 
complexes have been the most extensively studied and best characterized in yeast, 
fruit flies and mammalian model systems6. There are two distinct mammalian 
(m)SWI/SNF complexes – BRG1-associated factor (BAF) and polybromo BRG1-
associated factor (PBAF) – that share common core components, but also retain 
certain exclusive components4,6. Recent large-scale genome sequencing studies have 
revealed that genes encoding mSWI/SNF components are frequently mutated in a 
variety of human cancers. Of these, the most well studied are the shared components 
SMARCA4/2 (BRG1/BRM), SMARCB1 (SNF5/BAF47), the PBAF-specific 
component PBRM1 (BAF180), and the BAF-specific component SMARCF1 
(ARID1A/BAF250A)4,7. 
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Several studies have characterized the essential role of mSWI/SNF complexes 
in differentiation of various cell lineages, through its cooperation with tissue-specific 
transcription factors8-10. Since it is thought that there are several hundred variants of 
the mSWI/SNF complexes based on combinatorial assembly of cell type-specific 
components, these variant subunits may dictate the binding to lineage-specific factors 
and thus modulate mSWI/SNF activity at tissue-specific loci11-13. This would in part 
explain the tissue-specific cancer phenotypes of inactivating mutations of mSWI/SNF 
components observed in mouse models, and the distinct range of cancers associated 
with mutations in each mSWI/SNF subunit in humans4. 
With respect to the key targets of mSWI/SNF regulation, studies in different 
model systems have revealed direct interactions with TSGs such as RB and TP5314-17, 
suggestively in a functionally redundant manner, as well as with oncogenes such as 
MYC18-20. They have also been found to interact with nuclear-hormone receptors, and 
stem cell maintenance/differentiation factors21-25. Thus, mSWI/SNF modulates critical 
growth and signaling pathways that are tightly linked to the development of cancer. 
 
5.2 ARID1A Mutations in Human Cancer 
Recent human cancer genome sequencing studies have identified frequent 
inactivating ARID1A mutations in ovarian26,27, endometrial28-31, esophageal32-34, 
gastric35-38, colorectal39-43, liver44-50, pancreatic51-54, breast40,55-59, bladder60,61, 
melanoma2,62, lymphoma63-66, neuroblastoma67,68 and lung cancers2,40,69-71. Reduced 
ARID1A expression has also been detected at the protein level in certain precancerous 
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lesions, suggesting a critical role for loss of ARID1A function in tumor 
initiation26,30,58,72-80. 
In addition to the correlative genomic data implicating ARID1A as a tumor 
suppressor in human cancers, functional proof for its role in carcinogenesis has been 
elucidated more recently with the help of multiple different mouse models25,81-85. Due 
to the fact that Arid1a is heterozygous lethal in mice25, in vivo analyses of function 
necessitate conditionally knocking it out in a tissue-specific manner. To date, this 
experiment has not been done in the mammary gland in the context of breast 
carcinogenesis, although it is now known that ARID1A is deleted in a significant 
fraction of human mammary tumors, and that low ARID1A expression in tumors of 
breast cancer patients correlates significantly with poorer prognosis and overall 
survival55,57,86,87. 
In my research, I have identified Arid1a as being recurrently deleted in 
mammary tumors that arise spontaneously in the Chaos3 mouse model for breast 
cancer, and have shown that the loss of a single allele of Arid1a is required for 
maintaining proliferation and growth of cancer cells derived from this model. This is 
the first mouse model to characterize Arid1a as a tumor suppressor gene in sporadic 
mammary tumors, thus adding to the mounting in vivo evidence of the importance of 
Arid1a function in carcinogenesis.  
 
5.3 Mechanisms of ARID1A Tumor Suppression  
Exome sequencing studies have not only shed light on the frequency of 
ARID1A mutations in human cancers, but have also revealed cooccurring/mutually 
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exclusive mutations in other cancer pathways, suggestive of potential tumor 
suppressive mechanisms.  
In ovarian cancer, inactivating ARID1A mutations commonly coexist with 
activating phosphatidylinositol 3-kinase (PI3K) mutations88-91. A recent study using a 
mouse model in which ARID1A was conditionally deleted in ovarian surface epithelial 
cells showed that cooccurring mutations in the gene encoding the catalytic subunit of 
PI3K (PIK3CA) were essential for the formation of ovarian clear cell carcinomas in 
vivo81. They further demonstrated that these two pathways converge on carcinogenic 
cytokine signaling, suggesting a protective role for ARID1A against tumor formation 
driven by inflammation.  
In endometrial91,92, gastric93,94, esophageal74 and breast55 carcinomas, 
inactivating ARID1A and TP53 mutations frequently occur in a mutually exclusive 
manner. A study using an ovarian cancer model showed that ARID1A can physically 
interact with TP53 and help guide p53-mediated transcriptional regulation in 
association with the mSWI/SNF complex17. My thesis work corroborates this model in 
breast cancer, where we found that the p53 pathway is significantly activated upon 
overexpressing Arid1a in mammary tumor cells, and its tumor suppressive activity 
appears to be dependent on the presence of functional wild-type p5395. 
Another interesting study showed that inactivating Arid1a following induced 
injury in the liver and outer ear of a mouse model promotes tissue regeneration by 
curbing chromatin access of specific transcription factors that promote differentiation 
and suppress proliferation, thus revealing a role for ARID1A in maintaining normal 
organ structure and function85. 
 96 
 
Mechanistically, mSWI/SNF complexes have been found to function at both 
promoters and enhancers of genes, depending on the cell/tissue type96-98. Since the 
ARID domain-DNA binding is essential for mSWI/SNF activity99, chromatin 
immunoprecipitation (ChIP) of ARID1A would be one way in which to determine 
direct binding patterns of mSWI/SNF in a specific biological context. One study 
conducted ChIP-sequencing of ARID1A in a human liver cancer cell line (HepG2), 
and concluded that in this context ARID1A regulates expression primarily at the 
transcriptional start sites of genes100. A different study conducted ChIP-sequencing in 
a human colorectal cancer cell line (HCT116) with and without ARID1A, and showed 
that in this context ARID1A normally targets mSWI/SNF complexes to enhancers, 
where they coordinate with other transcription factors to regulate gene activation84. 
Taken together, these important studies have helped elucidate some possible 
mechanisms by which ARID1A functions as a tumor suppressor in different biological 
contexts, while also revealing how much more we still need to understand to better 
characterize its role in normal development and carcinogenesis. 
 
5.4 A Potential Haploinsufficient Role for ARID1A Tumor Suppression 
The striking observation that ARID1A is often heterozygously deleted/mutated 
in a spectrum of cancers, including breast57,86, ovarian101, pancreatic52,54 and renal102 
carcinomas, suggests that loss of function of a single allele may be sufficient to 
contribute to carcinogenesis. 
Studies using models in which Arid1a was monoallelically and biallelically 
deleted in different cell types have revealed the apparent lineage-specific effect of 
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Arid1a haploinsufficiency in carcinogenesis. Biallelic deletions of Arid1a in mouse 
ovarian epithelial cells were necessary to drive formation of ovarian clear cell 
carcinomas, suggesting that in this model, Arid1a likely follows the canonical ‘two-
hit’ model of tumor suppression81. However, in comparing HCT116 isogenic cell lines 
bearing monoallelic and biallelic deletions of ARID1A, partial loss of ARID1A 
function was found to affect enhancer activity and gene transcription, suggestive of a 
haploinsufficient effect in this model84. 
In my research, I have attempted to approach this question using a mammary 
tumor cell line derived from the Chaos3 mouse model for sporadic breast cancer, in 
which only one allele of Arid1a is intact and expressed. I have utilized a 
CRISPR/dCas9-based system to study the effect of endogenously restore Arid1a 
expression to biallelic levels in these tumor cells. Through these experiments, I have 
shown that restoring Arid1a expression to “wild-type” levels is sufficient to 
significantly reduce cancer cell proliferation and colony formation rates in vitro. 
 
5.5 Therapeutic Intervention in ARID1A Mutant Cancers 
Since mSWI/SNF components are altered in nearly 20% of all human cancers, 
identifying mechanisms by which we can therapeutically target these cancers would be 
extremely important and beneficial. Recent studies have shown that in some models 
mSWI/SNF-mutant cancers depend on residual mSWI/SNF complexes for malignant 
growth, while in others they rely on co-dependent oncogenic/tumor suppressive 
pathways7. Multiple synthetic lethal screens have been conducted to identify such 
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interactions which may be exploited for targeted therapy of mSWI/SNF-driven 
cancers7,103.  
With respect to cancers in which ARID1A is altered/mutated, associated 
gene/pathway vulnerabilities identified thus far are ARID1B, PIK3/AKT, EZH2, 
YES1, PARP and ATR104-108. These studies use a variety of human cancer cell lines as 
well as in vivo mouse models, all of which are based on inactivating ARID1A point 
mutations.  
As we know that there is a significant subset of tumors that are heterozygously 
deleted for ARID1A, but still retain low levels of expression from the remaining allele, 
a compelling therapeutic avenue to explore would be in trying to activate the 
remaining intact allele in these tumors. To date, the activation of TSGs as a method of 
clinical cancer treatment has been mainly through indirect and indiscriminate methods, 
by using so-called “Epi-drugs” (epigenetic drugs) that inhibit epigenetic enzymes – 
mainly DNA methyltransferase inhibitors (DNMTis) and histone deacetylase 
inhibitors (HDACis) – and result in gene upregulation109. Current FDA approved 
DNMTis (eg. azacitidine and decitabine) and HDACis (eg. vorinostat and 
romidepsin), are only effective on TSGs that are silenced by these epigenetic 
mechanisms, but due to their lack of target selectivity, can cause detrimental genome 
wide off-target effects, such as the upregulation of prometastatic genes109-111. 
Single gene cancer therapy has been a relatively unexplored method of 
treatment up till this point. One study conducted nearly ten years ago explored this 
possibility by administering wild-type TP53 (in combination with standard 
chemotherapy) using replication-deficient adenoviral vectors, to a group of patients 
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with primary stage III ovarian cancers that were mutant for p53112. While this trial 
proved unsuccessful,  amongst the main reasons attributed to its failure were (a) poor 
infective efficiency of the vectors used for transmission of the gene (b) the potential 
dominant-negative effect of mutant p53 that was present in these tumors113. The first 
issue represents a fixable technical problem, and current adenoviral vectors are greatly 
improved in their efficacy of delivery114-116. The second issue is specific to mutant 
TP53 function, and would not necessarily be relevant to other tumor suppressor genes. 
Thus, this is still an important therapeutic avenue that could be revisited and explored, 
as we gain more knowledge of genes that have potent tumor suppressive activity on 
their own, such as ARID1A. 
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Abstract 
It is estimated that ~25% of breast cancer cases have a familial basis, but the 
susceptibility genes underlying heritable predisposition remain largely unknown.  
Identification of genomic variants contributing to cancer susceptibility is complicated 
by the breadth of genetic diversity between individuals and populations, differences in 
the biological subtypes of breast cancers, and differing environmental factors.  These 
issues can be circumvented using mouse cancer models with defined genetic 
backgrounds in a controlled environment. Here we utilize the Chaos3 mouse model 
which, by virtue of a point mutation in the Mcm4 DNA replication gene that leads to 
genomic instability, causes spontaneous mammary tumors in the C3HeB/FeJ (C3H) 
strain background, but other cancer types in the C57BL/6J (B6) strain background.  
Studies of F1 and F2 (B6xC3H) -Mcm4Chaos3/Chaos3 female mice revealed a spectrum of 
cancer types driven by the Mcm4Chaos3 mutation, and genotyping of 189 F2 animals 
indicated that the genetic architecture of genetic susceptibility and resistance to 
mammary tumorigenesis and other tumor types is complex.  However, one 
susceptibility locus contained Tln1, a gene involved in integrin activation and focal 
adhesion to the extracellular matrix.  Remarkably, we identified a mutation 
(Glu1910Lys) in the C3H allele of Tln1 that arose in our stock line of C3H-
Mcm4Chaos3 mice.  Subsequent breeding studies revealed that this Tln1 mutation, which 
we hypothesize to be either a hypermorphic or a gain-of-function allele, increased the 
proportion of C3H-Chaos3 mice that developed mammary tumors.  These results 
implicate Tln1 as a breast cancer modifier. 
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Gene Expression Alterations in Tln1 Mutant Mammary Cells 
To determine if the Tln1 mutation impacts gene expression in a manner that might 
explain the heightened mammary tumor susceptibility, I conducted RNA-seq to 
identify differentially expressed (DE) genes in Tln1 WT vs Tln1K mammary glands of 
3-month-old nulliparous females. This revealed 64 DE genes (FPKM>5; log2 >1) 
(Table. A1). Six of the most highly DE genes (log2 >3) were selected for validation by 
qRT-PCR, and five were confirmed to be markedly upregulated (Fig. A1A). The three 
genes that were most most highly upregulated in mammary glands (Spp1, Cck and 
Ucp1) were either unchanged or upregulated to a smaller degree (Spp1) in tail and 
gonadal adipose tissue (Fig. A1B, C, respectively).  
Of the highly upregulated genes, the two that have plausible roles in 
tumorigenesis are Spp1 and Ucp1. SPP1 (osteopontin) has long been known as a 
marker for epithelial cell transformation, and has been shown in several studies to 
increase tumorigenicity and metastasis in multiple cancer types, including breast 
cancer1,2. The SPP1 protein contains an integrin recognition motif3, through which it 
helps control cell adhesion and motility4.  UCP1 (thermogenin) is a member of the 
family of uncoupling mitochondrial proteins that is highly expressed in brown adipose 
tissue, and has been shown to play a role in “fat-browning” of white adipose tissue in 
phenomenon of cancer-associated cachexia5. A previous study has shown that 
overexpressing UCP1 in cancer-associated fibroblasts increases the release of ATP-
rich vesicles extracellularly, thus stimulating the growth of neighboring epithelial 
cancer cells in a paracrine manner6. 
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Table A-A1. Differentially expressed genes in Tln1 mutant mammary gland cells. 
GENE SYMBOL
log2 
(fold_change)
GENE NAME
Ucp1 6.5 uncoupling protein 1 (mitochondrial, proton carrier)
Lalba 4.8 Lactalbumin, alpha
Fabp3 3.9 fatty acid binding protein 3, muscle and heart
Foxi1 3.7 Forkhead Box I1
Cck 3.6 Cholecystokinin
Spp1 3.6 Secreted Phosphoprotein 1
Fam25c 2.9 family with sequence similarity 25, member C
Clic6 2.3 chloride intracellular channel 6
1810010D01Rik 2.3
S100a8 2.2 S100 calcium binding protein A8 (calgranulin A)
Csn1s2a 2.1 casein alpha s2-like A
S100a9 2.1 S100 calcium binding protein A9 (calgranulin B)
Ltf 1.9 lactotransferrin
Ngp 1.8 neutrophilic granule protein 
Btn1a1 1.7 butyrophilin, subfamily 1, member A1
Csn2 1.6 casein beta
Mid1 1.6 midline 1
Anxa8 1.6 annexin A8
Mest 1.4 mesoderm specific transcript
Slc39a8 1.4 solute carrier family 39 (metal ion transporter), member 8
Vnn1 1.3 vanin 1 
Scnn1b 1.3 sodium channel, nonvoltage-gated 1 beta 
Tspan1 1.3 tetraspanin 1
Pdk4 1.3 pyruvate dehydrogenase kinase, isoenzyme 4
Tmem56 1.1 transmembrane protein 56
Slc12a2 1.1 solute carrier family 12, member 2
Clca2 1.1 chloride channel calcium activated 2 
Slc5a5 1.1 solute carrier family 5 (sodium iodide symporter), member 5
Tmprss2 1.1 transmembrane protease, serine 2
Agps 1.1 alkylglycerone phosphate synthase
Hey1 1.1 hairy/enhancer-of-split related with YRPW motif 
Col9a1 1.1 collagen, type IX, alpha 1
Rtp4 -1 receptor transporter protein 4 
Agtr1a -1.1 angiotensin II receptor, type 1a 
Oas1a -1.2 2'-5' oligoadenylate synthetase 1A
Thrsp -1.2 thyroid hormone responsive
Arc -1.2 activity regulated cytoskeletal-associated protein
Bst2 -1.2 bone marrow stromal cell antigen 2 
Egr2 -1.2 early growth response 2 
Crabp1 -1.3 cellular retinoic acid binding protein I
Cmpk2 -1.3 cytidine monophosphate (UMP-CMP) kinase 2, mitochondria
Usp18 -1.3 ubiquitin specific peptidase 18
Lrrc15 -1.4 leucine rich repeat containing 15 
Dhx58 -1.4 DEXH (Asp-Glu-X-His) box polypeptide 58
Mx2 -1.4 MX dynamin-like GTPase 2 
Igfbp2 -1.5 insulin-like growth factor binding protein 2
Zbp1 -1.6 Z-DNA binding protein 1
Oas2 -1.6 2'-5' oligoadenylate synthetase 2
Gzmb -1.6 granzyme B 
Calca -1.6 calcitonin/calcitonin-related polypeptide, alpha
Isg20 -1.6 interferon-stimulated protein
Oasl2 -1.7 2'-5' oligoadenylate synthetase-like 2
Mx1 -1.7 MX dynamin-like GTPase 1 
Ifit1 -1.7 interferon-induced protein with tetratricopeptide repeats 1
Defb1 -1.7 defensin beta 1
Irf7 -2.1 interferon regulatory factor 7
Ifit3 -2.1 interferon-induced protein with tetratricopeptide repeats 3
I830012O16Rik -2.1
Wfdc12 -2.3 WAP four-disulfide core domain 12
Oasl1 -2.3 2'-5' oligoadenylate synthetase-like 1
Oas3 -2.3 2'-5' oligoadenylate synthetase 3
Isg15 -2.4  Ubiquitin-Like Modifier
Sct -2.8 secretin
Pnmt -2.9 Phenylethanolamine N-Methyltransferase
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Figure A-A1. Top DE genes with roles in tumorigenesis. (A) qRT-PCR validation 
of the most highly upregulated genes in Tln1 mutant mammary cells. qRT-PCR to 
assay expression of top three upregulated genes in (B) tail and (C) gonadal adipose 
tissue controls. 
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Appendix B 
This appendix represents my work in generating an Arid1a conditional knock out 
(CKO) mouse model bearing the Chaos3 mutation, with the purpose of determining 
whether loss of Arid1a is a driver of mammary carcinogenesis in this model. 
To assess whether conditional deletions (homozygous and/or heterozygous) of 
Arid1a in the mammary gland is sufficient to drive tumor formation at a faster rate in 
the Chaos3 background, we utilized a mouse model in which exon eight of Arid1a is 
floxed by two LoxP sites, which has been previously verified to result in a loss-of-
function allele1. The floxed Arid1a allele was made congenic in the C3Heb/FeJ mouse 
strain bearing the Mcm4Chaos3 allele through two rounds of speed congenics, followed 
by selection of the best male breeders for subsequent matings (Figures A-B1). I then 
bred nulliparous female mice of the relevant genotypes, either with or without the 
Talin1 point mutation, setting up two independent cancer screens (Figure A-B2). 
These mice also contained a MMTV-Cre transgene necessary for catalyzing the 
Arid1a deletions, that I bred into the original C3H-Chaos3 strain background, using a 
model that had been previously described as a “less efficient” Cre2 to avoid any 
potential problems arising from “leaky” Cre expression. 
Following the development of mammary tumors in some of these mice, we 
assayed samples of the tumor tissues to confirm the deletion of Arid1a. Unfortunately, 
we found that none of the tumors had the expected Arid1a deletions, and attributed 
this to the unsuccessful expression of the MMTV-Cre allele. We are currently in the 
process of repeating this experiment using a pre-packaged Cre recombinant adeno 
virus, which we will directly inject into the mammary glands for immediate deletion 
of the targeted floxed Arid1a allele. We have tested this Cre in mammary tumor cells 
generated from the unsuccessfully edited tumors mentioned above, bearing intact 
LoxP sites. These preliminary experiments have shown promising results indicating a 
more powerful Cre delivery system.   
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Figure A-B1: Genotyping results from two rounds of speed congenics. Speed 
congenics results representing (A) first round and (B) second round of enrichment for 
the C3Heb/FeJ genotype bearing the “floxed” Arid1a allele. Male breeders were 
selected for subsequent matings as follows – Round #1: JS6, JS 5 and JS 3; Round #2: 
JS 08, JS 03 and JS 10. 
(A) 
(B) 
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Figure A-B2: Schematic matings for Arid1a CKO cancer screens. Two 
independent cancer screens were set up with mice that were (A) wild-type for Talin1 
mutation or (B) Talin1 mutant. All mice contained the MMTV-Cre allele, with either 
wild-type, heterozygous or homozygous alleles of floxed Arid1a. N=15 for each 
genotype in both screens. 
(A) 
(B) 
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